

ENANTA PHARMACEUTICALS, INC.
500 Arsenal Street
Watertown, Massachusetts 02472
(617) 607-0800

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD MARCH 2, 2023

The 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) of Enanta Pharmaceuticals, Inc. (“Enanta”), a Delaware corporation, will be held virtually at **5:00 p.m. Eastern time on Thursday, March 2, 2023**, via live audio webcast at www.proxydocs.com/ENTA for the following purposes:

1. To elect two Class I directors to serve until the 2026 Annual Meeting of Stockholders.
2. To approve an amendment to Enanta’s 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.
3. To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the accompanying proxy statement.
4. To ratify the appointment of PricewaterhouseCoopers LLP as Enanta’s independent registered public accounting firm for the 2023 fiscal year.
5. To transact any other business that may properly come before the meeting or any adjournment thereof.

The record date for the 2023 Annual Meeting is January 10, 2023. Accordingly, only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.

You may vote on these matters in person (virtually), by proxy or via the internet or telephone. In order to provide our stockholders with a means to attend the annual meeting in a manner that is convenient for our stockholders, we have elected to continue to hold our annual meeting via remote communication. You may attend the virtual annual meeting and vote your shares during the meeting by visiting our annual meeting website at www.proxydocs.com/ENTA.

Whether or not you plan to attend the virtual meeting, we ask that you vote promptly so that your shares will be represented and voted at the meeting in accordance with your wishes.

You are entitled to participate in and submit questions in writing during the annual meeting if you were a stockholder as of the close of business on January 10, 2023. To participate in the 2023 Annual Meeting virtually via the Internet, please visit www.proxydocs.com/ENTA. In order to attend, you must register in advance at www.proxydocs.com/ENTA prior to the deadline of **March 1, 2023 at 5:00 pm Eastern Time**. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will permit you to submit questions. You will not be able to attend the 2023 Annual Meeting in person. For instructions on how to vote your shares, please refer to the instructions on the Notice of Internet Availability of Proxy Materials you received in the mail, the section titled “*How do I Vote*” in the Proxy Statement or, if you requested to receive printed proxy materials, your enclosed proxy card. A list of our registered holders as of the close of business on the record date will be made available to stockholders during the meeting at www.proxydocs.com/ENTA.

By order of the Board of Directors,

January 20, 2023

Nathaniel S. Gardiner
Secretary

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MARCH 2, 2023

This proxy statement and our Annual Report are available online at the “Investors – 2023 Annual Meeting Materials” section of our website at www.enanta.com. For more information about how to access our virtual meeting, please visit the “Investors – 2023 Annual Meeting Materials” section of our website at www.enanta.com or contact Investor Relations at (617) 607-0710.

TABLE OF CONTENTS

	<u>Page</u>
INFORMATION CONCERNING SOLICITATION AND VOTING	1
QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING	1
BENEFICIAL OWNERSHIP OF COMMON STOCK	5
PROPOSAL 1: Vote to elect Class I directors	8
PROPOSAL 2: Vote to approve an increase in the number of shares reserved for issuance under the 2019 Equity Incentive Plan	13
PROPOSAL 3: Vote to approve, on an advisory basis, the compensation paid to our named executive officers	21
PROPOSAL 4: Vote to ratify appointment of independent registered public accounting firm	21
CORPORATE GOVERNANCE	22
Board and Committee Matters	22
Certain Relationships and Related Transactions	25
EXECUTIVE OFFICERS	26
EXECUTIVE COMPENSATION	28
Compensation Discussion and Analysis	28
Compensation Committee Report	40
Summary Compensation Table	41
2022 Grants of Plan-Based Awards	44
2022 Options Exercised and Stock Awards Vested	46
Outstanding Equity Awards at Fiscal 2022 Year-End	47
Potential Payments Upon Termination, Including Termination After a Change in Control Transaction	49
CEO Pay Ratio	51
DIRECTOR COMPENSATION	52
AUDIT COMMITTEE REPORT	54
STOCKHOLDER MATTERS	56
Appendix A	A-1

PROXY STATEMENT

INFORMATION CONCERNING SOLICITATION AND VOTING

We are soliciting proxies from our stockholders to vote at our 2023 Annual Meeting of Stockholders, or at any continuation, postponement or adjournment thereof, for the purposes discussed in this proxy statement. The annual meeting will be held virtually at **5:00, p.m. Eastern time on Thursday, March 2, 2023**, at www.proxydocs.com/ENTA. For more information on how to access the virtual meeting, please visit the “Investors – 2023 Annual Meeting Materials” section of our website at www.enanta.com or contact Investor Relations at (617) 607-0710.

The proxy materials, including this proxy statement and our 2022 annual report to stockholders, are being distributed and made available on the internet at the “Investors – 2023 Annual Meeting Materials” section of our website at www.enanta.com on or about January 20, 2023.

This proxy statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully.

All references in this proxy statement to a particular year, e.g., 2022, refer to our twelve-month fiscal year ended on September 30 of that year, e.g., September 30, 2022, unless the context indicates otherwise.

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING

Why did I receive these materials?

We are soliciting proxies for our annual meeting of stockholders to be held on Thursday, March 2, 2023. You are receiving a proxy statement because you owned shares of our common stock on January 10, 2023, the record date for the annual meeting, and that ownership entitles you to vote at the meeting. By use of a proxy, you can vote, whether or not you attend the meeting at www.proxydocs.com/ENTA.

When and where is the Annual Meeting?

The annual meeting will be held virtually at **5:00 p.m. on Thursday, March 2, 2023**, or at any future date and time following an adjournment or postponement of the meeting, at www.proxydocs.com/ENTA. In order to attend, you must register in advance at www.proxydocs.com/ENTA prior to the deadline of March 1, 2023, at 5:00 pm Eastern Time. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will permit you to submit questions.

What proposals will be voted on at the Annual Meeting?

The four proposals to be considered and voted on at the annual meeting, as set forth in the accompanying Notice of Annual Meeting of Stockholders, are:

- (i) the election of two Class I directors;
- (ii) an amendment to increase the number of shares reserved for issuance under the 2019 Equity Incentive Plan;
- (iii) an advisory vote on executive compensation; and

- (iv) the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2023 fiscal year.

As far as we know, the only matters to be brought before the annual meeting are those referred to in this proxy statement. If any additional matters are presented at the annual meeting, the persons named as your proxies may vote your shares in their discretion.

How do I vote?

Beneficial Owner: Shares Registered in the Name of a Broker or Bank.

If on January 10, 2023 your shares were held in an account at a brokerage firm, bank, dealer, or other similar organization, then your shares are held in “street name” and you are the beneficial owner and not the record owner of the shares. If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a notice of internet availability with voting instructions from that organization rather than from us. If you are a beneficial owner, you can vote in the following ways:

- ***By Mail:*** If you requested and received a paper copy of our proxy materials, you may vote using the proxy card supplied by your broker or bank by completing and mailing that proxy card to ensure that your vote is counted.
- ***By Internet/Telephone:*** To vote over the internet, or by telephone, please follow any instructions provided by your broker or bank if either alternative is made available to you.
- ***At Virtual Meeting:*** If you have followed the procedures described in this proxy statement for obtaining credentials for the meeting, you may vote online while attending the meeting virtually at www.proxydocs.com/ENTA and following the instructions for stockholder voting. In order to attend, you must register in advance at www.proxydocs.com/ENTA prior to the deadline of **March 1, 2023, at 5:00 pm Eastern Time**. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will permit you to submit questions.

Stockholder of Record: Shares Registered in Your Name.

If on **January 10, 2023**, your shares were registered directly in your name with our transfer agent, then you are a stockholder “of record.” If you are a stockholder of record, you may vote in person at the annual meeting or by any of the methods listed below. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. There are four ways for you to vote:

- ***By Mail:*** To vote using the proxy card, please complete, sign and date the proxy card furnished to you with the notice of this meeting and return it promptly in the envelope provided. If you return your signed proxy card to us before the annual meeting, we will vote your shares as you direct.
- ***By Internet:*** To vote via the internet, access the website for our meeting at: www.proxypush.com/enta using the voter control number printed on the proxy card furnished to you with the notice of this meeting. Your shares will be voted in accordance with your instructions. You must specify how you want your shares voted or your internet vote cannot be completed and you will receive an error message. If you vote on the internet, you may also request electronic delivery of future proxy materials.
- ***By Telephone:*** If you live in the United States or Canada, you may vote by proxy by calling toll-free 1-866-892-1702 and by following the instructions. When voting, you must have the voter control number printed on the notice of internet availability furnished to you.
- ***At Virtual Meeting:*** You may vote online while attending the meeting virtually at www.proxydocs.com/ENTA and following the instructions for stockholder voting. In order to

attend, you must register in advance at www.proxydocs.com/ENTA prior to the deadline of March 1, 2023, at 5:00 pm Eastern Time. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will permit you to submit questions.

Who can vote at the Annual Meeting?

Only stockholders of record at the close of business on January 10, 2023, the record date, are entitled to notice of, and to vote at, the annual meeting or any adjournment or postponement of the meeting. On the record date, we had 20,886,433 outstanding shares of common stock, each of which is entitled to one vote upon each of the matters to be presented at the meeting.

You may contact our Secretary and General Counsel, Nathaniel S. Gardiner, at (617) 607-0800 to make arrangements to review a copy of the stockholder list at our offices in Watertown, MA, between the hours of 9:00 a.m. and 5:00 p.m., Eastern time, on any business day from February 18, 2023, to the time of the annual meeting. It will also be necessary to plan a meeting time and place to provide access to our facility where the stockholder list is maintained.

See “*How do I vote*” above for more information regarding voting.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least a majority of the outstanding shares are represented by stockholders present at the meeting or present by proxy. On the record date, there were 20,886,433 shares outstanding and entitled to vote. Thus, 10,443,217 shares must be represented by stockholders present at the meeting in person or by proxy to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, a majority of the shares present at the meeting may vote to adjourn the meeting to another date.

How are votes counted?

Votes will be counted by the inspector of election appointed for the meeting, who will separately count “For” and “Withhold” and, with respect to proposals other than the election of directors, “Against” votes, abstentions and broker non-votes. Abstentions and broker non-votes have no effect and will not be counted towards the vote total for any proposal.

If your shares are held by your broker in “street name” and you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items. Discretionary items are proposals considered routine on which your broker may vote shares held in street name in the absence of your voting instructions. The ratification of the appointment of Enanta’s independent registered public accounting firm for the 2023 fiscal year will be the only discretionary matter on the agenda. Non-discretionary items are matters such as mergers, stockholder proposals, executive compensation and elections of directors. On non-discretionary items for which you do not give your broker instructions, the shares will be treated as broker non-votes.

What if I return a proxy card but do not make specific choices?

If you return a signed and dated proxy card without marking any voting selections, your shares will be voted

- “For” our two nominees for director;

- “For” the amendment to increase the number of shares reserved for issuance under the 2019 Equity Incentive Plan;
- “For” the approval, on an advisory basis, of the compensation paid to our named executive officers; and
- “For” ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our 2023 fiscal year.

Can I change my vote after submitting my proxy?

Yes, if you are a record holder you can revoke your proxy in any one of four ways:

- You may revoke your vote by voting again by telephone prior to the close of the telephone voting facility.
- You may revoke your vote by voting again over the internet prior to the close of the internet voting facility.
- You may send a written notice that you are revoking your proxy to our Secretary, Nathaniel S. Gardiner, c/o Enanta Pharmaceuticals, Inc., 500 Arsenal Street, Watertown, Massachusetts 02472.
- You may attend the meeting virtually and vote online during the meeting.

If you are a beneficial owner and your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank for revoking your proxy.

What is the vote required for a proposal to pass?

- Proposal 1. Directors are elected by a plurality of the votes cast by the holders of the shares represented in person or by proxy. Broker non-votes and proxies marked to withhold authority with respect to the election of one or more Class I directors will not be voted with respect to the director indicated. The two director nominees receiving the highest number of votes will be elected.
- Proposal 2. The affirmative vote of the holders of a majority of the votes cast at the meeting is required for approval of the proposed amendment to increase the number of shares reserved for issuance under the 2019 Equity Incentive Plan. Abstentions and broker non-votes will have no effect on the voting outcome.
- Proposal 3. The affirmative vote of the holders of a majority of the votes cast at the meeting is required for approval of the advisory resolution to approve the compensation of our named executive officers. Abstentions and broker non-votes will have no effect on the voting outcome.
- Proposal 4. The affirmative vote of the holders of a majority of the votes cast at the meeting is required to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2023 fiscal year. Abstentions and broker non-votes will have no effect on the voting outcome.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the annual meeting. Final voting results will be published in a Current Report on Form 8-K, or Form 8-K, that we expect to file with the Securities and Exchange Commission, or SEC, within four business days after the annual meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the annual meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to mailing the proxy materials, our officers, directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Officers, directors and employees will not be paid any additional compensation for soliciting proxies. We will also request brokerage houses, custodians, nominees, and fiduciaries to forward copies of the proxy material to those persons for whom they hold shares, and we will reimburse those record holders for their reasonable expenses in transmitting this material. In addition, we have engaged The Proxy Advisory Group, LLC to assist in the solicitation of proxies and provide related advice for a services fee and reimbursement of customary disbursements, which are not expected to exceed \$20,000, in total.

Householding of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be “householding” our proxy statements and annual reports. This means that only one copy of our proxy statement and annual report to stockholders may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you if you call or write us at our principal executive offices, 500 Arsenal Street, Watertown, Massachusetts 02472, Attn: Investor Relations, telephone: (617) 607-0710. In the future, if you want to receive separate copies of the proxy statement or annual report to stockholders, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address and telephone number.

BENEFICIAL OWNERSHIP OF COMMON STOCK

The following table and footnotes set forth certain information regarding the beneficial ownership of our common stock as of December 15, 2022 by (i) persons known by us to be beneficial owners of more than 5% of our common stock, (ii) each of our current executive officers named in the Summary Compensation Table included in “Executive Compensation” below, (iii) our current directors and (iv) all our current executive officers and directors as a group. The percentage of shares beneficially owned is computed on the basis of shares of our common stock outstanding as of December 15, 2022.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock that a person has the right to acquire within 60 days of December 15, 2022, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Except as otherwise indicated in the footnotes below, we believe the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the footnotes below, the address of the beneficial owner is c/o Enanta Pharmaceuticals, Inc., 500 Arsenal Street, Watertown, MA 02472.

Beneficial Owner	Beneficially Owned Number of Shares	
	Shares	Percent
BlackRock Inc. ⁽¹⁾	3,621,795	17.38%
Armistice Capital, LLC ⁽²⁾	2,072,000	9.94%
Farallon Capital Management, LLC ⁽³⁾	1,550,000	7.44%
The Vanguard Group, Inc. ⁽⁴⁾	1,476,910	7.09%
State Street Corp ⁽⁵⁾	1,377,417	6.61%
Jay R. Luly, Ph.D.	1,477,792 ^{†(6)}	6.83%
Yat Sun Or, Ph.D.	583,712 ^{†(7)}	2.77%
Nathaniel S. Gardiner, J.D.	273,719 ^{†(8)}	1.30%
Paul J. Mellet	204,751 ^{†(9)}	*
Scott T. Rottinghaus, M.D.	0	*
Bruce L. A. Carter, Ph.D.	50,375 ⁽¹⁰⁾	*
Mark G. Foletta	29,013 ⁽¹¹⁾	*
Yujiro Hata	13,081 ⁽¹²⁾	*
Kristine Peterson	45,625 ⁽¹³⁾	*
Lesley Russell, MBChB, MRCP	49,375 ⁽¹⁴⁾	*
Terry Vance	82,110 ⁽¹⁵⁾	*
All current directors and executive officers as a group (13 persons)	2,870,037 ^{†(16)}	12.70%

* Less than 1%

† Excludes all shares that may be issuable after December 15, 2022 under outstanding performance share units or relative total stockholder return units issued to management because, as of December 15, 2023 none of such shares were issuable within 60 days thereafter.

- (1) BlackRock Inc. reports that it holds, directly or through one or more of its subsidiaries, sole investment power with respect to all these shares, and sole voting power with respect to 3,535,019 of these shares and no voting power with respect to the remainder. This information is as of September 30, 2022, based solely on a Schedule 13F-HR filed by BlackRock Inc. on November 14, 2022. The address listed for BlackRock Inc. is 55 East 52nd Street, New York, NY 10055.
- (2) Armistice Capital, LLC reports that it holds, directly or through one or more of its subsidiaries, sole investment and voting power with respect to all of these shares. This information is based solely on a Schedule 13F-HR filed by Armistice Capital, LLC. on November 14, 2022. The address listed for Armistice Capital, LLC is 510 Madison Avenue, 7th Floor, New York, NY 10022.
- (3) Farallon Capital Management, LLC reports that it holds sole voting and dispositive power over all of these shares. This information is based solely on a Schedule 13F-HR filed by Farallon Capital Management, LLC on November 14, 2022. The address listed for Farallon Capital Management, LLC is One Maritime Plaza, Suite 2100, San Francisco, CA 94111.
- (4) The Vanguard Group, Inc. reports that it holds, directly or through one or more of its subsidiaries, (i) sole investment power and no voting power with respect to 1,442,983 of these shares, (ii) shared investment

power and sole voting power with respect to 15,639 of these shares and (iii) shared investment and no voting power with respect to 18,288 of these shares. This information is based solely on a Schedule 13F-HR filed by Vanguard Group, Inc. on November 14, 2022. The address listed for Vanguard Group, Inc. is P.O. Box 2600, V26, Valley Forge, PA 19482-2600.

- (5) State Street Corp reports that it holds, directly or through one or more of its subsidiaries, (i) sole investment power and no voting power with respect to 1,322,839 of these shares and (ii) sole investment and no voting power with respect to 54,578 of these shares. This information is based solely on a Schedule 13F-HR filed by State Street Corp on November 15, 2022. The address listed for State Street Corp is One Lincoln Street, Boston, MA 02111.
- (6) Consists of (i) 710,805 shares of common stock and (ii) 799,512 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (7) Consists of (i) 338,187 shares of common stock and (ii) 254,425 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (8) Consists of (i) 38,051 shares of common stock held directly, (ii) 28,107 shares of common stock held by grantor retained annuity trusts for the benefit of Mr. Gardiner and his two adult children, and (iii) 216,461 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (9) Consists of (i) 60,503 shares of common stock and (ii) 153,148 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (10) Consists of 50,375 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (11) Consists of 29,013 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (12) Consists of 13,081 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (13) Consists of 45,625 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (14) Consists of 49,375 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (15) Consists of (i) 15,295 shares of common stock and (ii) 66,815 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.
- (16) See Notes 6 through 15. Consists of (i) 1,108,007 shares of common stock and (ii) 1,762,030 shares of common stock issuable upon exercise of outstanding options that were exercisable within the 60-day period following December 15, 2022.

Delinquent Section 16(a) Reports

Our executive officers and directors and persons who own beneficially more than 10% of our equity securities are required under Section 16(a) of the Securities Exchange Act of 1934 to file reports of ownership and changes in their ownership of our securities with the SEC. They must also furnish copies of these reports to us. Based solely on a review of the copies of reports furnished to us and written representations that no other reports were required, we believe that for our 2022 fiscal year our executive officers, directors and 10% beneficial owners complied with all applicable Section 16(a) filing requirements, except that Dr. Rottinghaus filed one late Form 4 on August 11, 2022, with respect to a grant of restricted stock units and options on August 8, 2022.

PROPOSAL 1
ELECTION OF DIRECTORS

Our Board of Directors has fixed the number of directors at seven. Under our charter, our Board is divided into three classes, with each class having as nearly as possible an equal number of directors. The term of one class expires, with their successors being subsequently elected to a three-year term, at each annual meeting of stockholders. At the 2023 Annual Meeting, the two nominees named in this proxy statement as Class I Directors will be elected to hold office for three years until their successors are elected and qualified. The Board has nominated Bruce L.A. Carter, Ph.D. and Jay R. Luly, Ph.D. for re-election as Class I Directors at the upcoming annual meeting. Dr. Carter is an independent director as defined by applicable Nasdaq Stock Market standards governing the independence of directors. Dr. Luly is our Chief Executive Officer, or CEO. Each nominee has consented to serve, if elected. If any nominee is unable to serve, proxies will be voted for any replacement candidate nominated by our Board of Directors.

Votes Required

Directors will be elected by a plurality of the votes cast by the stockholders entitled to vote on this proposal at the meeting. Broker non-votes and proxies marked to withhold authority with respect to one or more Class I directors will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the election.

Nominees for Director and Current Directors

Current SEC rules require us to discuss briefly the specific experience, qualifications, attributes or skills that led the Board to conclude that each director or nominee for director should serve on our Board of Directors. The following matrix summarizes the significant experience and skills of each of our directors that we think is especially relevant to his or her service on our Board. We have also provided this discussion in a separate paragraph immediately below the biographical information provided for each director further below.

Board Experience Matrix (As of December 15, 2022)

Biotech Experience	Carter	Foletta	Hata	Luly	Peterson	Russell	Vance
Biotech Industry	✓	✓	✓	✓	✓	✓	✓
Business Development and M&A	✓	✓	✓	✓	✓		✓
Therapeutic Drug Development	✓		✓	✓		✓	
Finance and Audit		✓					✓
Strategic Partnering	✓	✓	✓	✓	✓		
Senior Executive Roles	✓	✓	✓	✓	✓	✓	
Public Company Boards	✓	✓	✓		✓	✓	

In accordance with Nasdaq’s recently adopted board diversity listing standards, we are also disclosing aggregated statistical information about our Board’s self-identified gender and racial characteristics and LGBTQ+ status as voluntarily confirmed to us by each of our directors. Each of the categories listed in the table below has the meaning used in Nasdaq Rule 5605(f). The statistical information set forth below is unchanged from the information provided in the proxy statement for our 2022 annual meeting of stockholders.

Board Diversity Matrix (As of December 15, 2022)
Total Number of Directors - 7

	<u>Female</u>	<u>Male</u>	<u>Non-Binary</u>	<u>Did Not Disclose Gender</u>
Directors	2	5	—	—
Number of Directors who identify in Any of the Categories Below:				
African American or Black	—	—	—	—
Alaskan Native or Native American	—	—	—	—
Asian	—	1	—	—
Hispanic or Latinx	—	—	—	—
Native Hawaiian or Pacific Islander	—	—	—	—
White	2	4	—	—
Two or More Races or Ethnicities	—	—	—	—
LGBTQ+	—	—	—	—
Did Not Disclose Demographic Background	—	—	—	—

The following table contains biographical information as of December 15, 2022, about the nominees for Class I directors and our current directors whose terms of office will continue after the annual meeting. The table includes information provided by the directors individually as to their age, current position, principal occupation and experience for the past five years, and the names of other public companies for which they currently serve as a director or have served as a director during the past five years.

As you read the disclosure, please keep in mind that any specific qualification, attribute or skill that is attributed to one director should not necessarily imply that other directors do not possess that qualification, attribute or skill. Furthermore, this disclosure does not impose on any director any duties, obligations or liability that are greater than the duties, obligations, and liability imposed on each other member of the Board.

Because the discussion of the specific experience, qualifications, attributes or skills of a director is to be made each year in light of Enanta’s business and structure at that time, the content of this discussion may change for one or more directors in future years.

<u>Name and Age</u>	<u>Business Experience During Past Five Years and Other Directorships</u>	<u>Director Since</u>
	<i>Class I Directors (present term expires in 2023; nominees for election at the Annual Meeting)</i>	
Bruce L. A. Carter, Ph.D. Age: 79	Bruce L.A. Carter, Ph.D. has served on our Board of Directors since November 2013 and as our non-executive Chairman of the Board since December 2015. Dr. Carter has been an Affiliate Professor in the Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He served as Executive Chairman of Immune Design Corp., a privately held biotechnology company, from November 2009 to November 2011 and he served as a director from 2000 to January 2009. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a public biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1998, Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a public pharmaceutical company. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. Dr. Carter serves as a director of Mirati Therapeutics, a public biopharmaceutical company. He also previously served during the past five years as an independent director of Dr. Reddy’s Laboratories Limited, a public pharmaceutical company.	2013

Name and Age	Business Experience During Past Five Years and Other Directorships	Director Since
Jay R. Luly, Ph.D. Age: 66	<p>Dr. Carter holds a Ph.D. in microbiology from Queen Elizabeth College, University of London and a B.Sc. with Honors in botany from the University of Nottingham, England.</p> <p>We believe that Dr. Carter is qualified to serve on our board of directors due to his business and scientific experience as a pharmaceutical executive in Europe and the United States and as chief executive officer of a biotechnology company, in addition, to his experience as a director of several companies in our industry.</p>	2003
Yujiro S. Hata Age: 48	<p><i>Jay R. Luly, Ph.D.</i> has served as our President and Chief Executive Officer and as a member of our board of directors since July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium's merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois at Urbana-Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley.</p> <p>We believe that Dr. Luly is qualified to serve on our board of directors due to his service as our President and Chief Executive Officer and his extensive knowledge of our company and industry.</p> <p style="text-align: center;"><i>Class II Directors (present term expires in 2024)</i></p> <p><i>Yujiro S. Hata</i> was elected to our board of directors in August 2021. Mr. Hata currently serves as Chief Executive Officer of IDEAYA Biosciences, an oncology-focused precision medicine company, which he founded in 2015 while an Executive-in-Residence at 5AM Ventures, a position he held from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, Inc and FLX Bio, Inc., both immuno-oncology companies, which he joined as start-ups and led through Flexus' acquisition by Bristol-Myers Squibb Co. in April 2015. Mr. Hata held business development roles at Onyx Pharmaceuticals from 2010 until its acquisition by Amgen in October 2013, serving most recently as Vice President, Corporate Development and Strategy. Previously he held business and corporate development roles at Enanta, Genome Therapeutics and ImClone Systems. Mr. Hata also serves as a director of Xencor, Inc., a biotechnology company. Mr. Hata obtained his B.A. in Chemistry from Colorado College and his M.B.A. from The Wharton School at the University of Pennsylvania.</p> <p>We believe that Mr. Hata is qualified to serve on our board of directors due to his executive management, business and corporate development and M&A experience in several biotechnology companies, both public and private.</p>	2021

Name and Age	Business Experience During Past Five Years and Other Directorships	Director Since
Kristine Peterson Age: 63	<p><i>Kristine Peterson</i> has served as a member of our board of directors since September 2017. Ms. Peterson has over 30 years of senior executive experience in commercial and business leadership roles in the pharmaceutical and biotechnology industry. From 2009 to 2016, Ms. Peterson served as Chief Executive Officer of Valeritas, Inc., a commercial-stage medical technology company where, under her leadership, the organization evolved from a research stage company to a commercial enterprise. Previously she held executive global marketing and commercial roles at Johnson & Johnson from 2004 to 2009, most recently as Company Group Chair, Biotech Sector, where she was responsible for commercial, R&D, and biologics manufacturing for biotech, oncology, immunology and cell therapy. From 2003 to 2004, she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals. Earlier in her career, she spent 20 years at Bristol-Myers Squibb Company in senior sales and marketing roles of increasing responsibility in a broad range of therapeutic areas that included Cardiovascular, Metabolic, Anti-infective, Virology, Neuroscience, Immunology/Inflammation, Pulmonary, and Oncology. Ms. Peterson currently serves on the Boards of Directors of Amarin Corporation plc, Immunocor, plc, ImmunoGen, Inc. and Paratek Pharmaceuticals, Inc., all of which are public biopharmaceutical companies. She also previously served during the past five years as an independent director of EyePoint Pharmaceuticals, Inc. She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign.</p> <p>We believe that Ms. Peterson is qualified to serve on our board of directors due to her executive management and sales and marketing experience in large pharmaceutical companies and smaller biotechnology companies and her other public company board experience.</p>	2017
Terry C. Vance Age: 66	<p><i>Terry C. Vance</i> has served as a member of our board of directors since June 2011. From June 2013 until November 2018, Mr. Vance was Chief Business Officer of BioMotiv, LLC, a drug development company affiliated with The Harrington Project. Until January 2018, Mr. Vance was a Managing Member of EGS Healthcare, a late-stage venture capital fund that he co-founded in 2000. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotechnology companies. Prior to Eagle, Mr. Vance was an investment banker, first with Salomon Brothers and then with Goldman Sachs, where he was a vice president in the Capital Markets Division. Mr. Vance received an AB from Princeton University and an MBA from Stanford University.</p> <p>We believe that Mr. Vance is qualified to serve on our board of directors due to his business and financial experience as a venture capital investor and investment banker in our industry.</p>	2011
Mark G. Foletta, Age 62	<p style="text-align: center;"><i>Class III Directors (present term expires in 2025)</i></p> <p>Mark G. Foletta was elected to our board of directors in June 2020. Mr. Foletta had been the Chief Financial Officer and Executive Vice President of Tocagen, Inc., a public biotechnology company, from</p>	2020

<u>Name and Age</u>	<u>Business Experience During Past Five Years and Other Directorships</u>	<u>Director Since</u>
---------------------	---	-----------------------

February 2017 until its merger with Forte Biosciences in June 2020. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Previously, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., a public diagnostics company. Mr. Foletta is an independent director of DexCom, Inc., a public medical device company where he also serves as Lead Director, and AMN Healthcare Services, Inc., a public healthcare services company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara.

We believe that Mr. Foletta’s considerable audit and financial experience in the biotechnology and healthcare sectors qualifies him to serve on our board of directors.

Lesley Russell,
MBChB, MRCP
Age: 62

Lesley Russell, MBChB, MRCP, was elected to our board of directors in November 2016. Dr. Russell served as Chief Medical Officer of Innocoll Holdings Plc., a public biotechnology company, from April 2016 until November 2017, prior to which Dr. Russell served as Chief Operating Officer and Chief Medical Officer of TetraLogic Pharmaceuticals, another public biotechnology company, from August 2013. Dr. Russell was a medical executive with Cephalon, Inc. from January 2000 to 2011, most recently as Executive Vice President and Chief Medical Officer from September 2006 until October 2011, when Cephalon was acquired by Teva Pharmaceuticals. Dr. Russell served as a Senior Vice President and Global Head, Research and Development for Global Branded Products from the acquisition until July 2012. Dr. Russell previously held positions in medical research at US Bioscience, Eli Lilly and Amgen. Dr. Russell is an independent director of Imugene Limited, an Australian public biotechnology company, Chimeric Therapeutics Limited, an Australian public biotechnology company. She also previously served during the past five years as an independent director of AMAG Pharmaceuticals, Inc., a public specialty pharmaceutical company, and Endocyte Pharmaceuticals, Inc., a public biotechnology company. Dr. Russell holds a Bachelor of Medicine, Bachelor of Surgery (MBChB) from the University of Edinburgh and is a member of the Royal College of Physicians (MRCP), UK.

2016

We believe that Dr. Russell is qualified to serve on our board of directors due to her business and drug development experience, her service on other public company boards and her knowledge of our industry.

Recommendation

We recommend a vote “FOR” each of our two Class I director nominees.

PROPOSAL 2

AMENDMENT TO 2019 EQUITY INCENTIVE PLAN

We are asking stockholders to approve an amendment to our 2019 Equity Incentive Plan, which we refer to as the 2019 Equity Plan, to increase the number of shares of our common stock reserved for issuance under the plan by 975,000 shares.

Reasons for Seeking Stockholder Approval

The following reasons for approving the proposed amendment are discussed in greater detail in the following pages:

- Equity awards are a key part of our compensation program for employees generally
- Our equity program is designed to incentivize performance
- We have managed our equity burn rate efficiently, averaging 3.97% per year
- Our equity award overhang reflects 9+ years without dilutive equity financings
- The proposed increase is projected to enable needed recruitment and retention into 2024

Equity Awards are a Key Part of our Compensation Program for Employees Generally

Our Compensation Committee believes that equity compensation has been, and will continue to be, a critical component of our compensation program because it develops a culture of ownership among our employees and aligns their interests with the interests of our stockholders. Unlike many companies, we have a practice of granting equity-based awards broadly throughout our organization, believing that we will succeed if all our employees feel invested in us, our business and our future. In 2023, we anticipate that we will continue to build our research and development team with plans to hire approximately 36 additional employees to support clinical development of our most advanced compounds. To date, we have successfully competed for top talent, often in direct competition with much larger pharmaceutical companies with greater resources, in part because of our use of equity-based compensation. In addition, we have to compete with other biotechnology companies, all of which use equity-based compensation as a key component of their compensation programs. We believe that equity awards are central to our employment value proposition and are necessary for us to continue competing for top talent as we grow.

As of December 31, 2022, there were 560,008 shares available for grant under the 2019 Equity Plan. Accordingly, without the proposed addition to the reserve in the 2019 Equity Plan, our ability to provide equity incentives for our planned new hires, as well as our existing employees and management team, would be severely limited. In turn, this would place us at a competitive disadvantage because our ability to attract, motivate and retain key personnel would be compromised during a critical growth period.

Our Equity Program is Designed to Incentivize Performance

As noted above, our broad-based equity program generally provides for stock option awards and restricted stock unit awards to all employees, which awards are designed to incentivize performance because no value is created unless our stock price increases from the date the options are granted. We grant stock options to new employees that are subject to 25% vesting on the first anniversary of employment with the balance vesting quarterly over the subsequent three years. In addition, we provide annual awards of stock options to all employees that are subject to quarterly vesting over four years from the date of grant. Since November 2020, our Compensation Committee has chosen to grant a portion of the annual equity award as restricted stock units that are subject to annual vesting over four years from the date of grant. The number of restricted stock units is

determined by reducing the number of stock options by a percentage set by our Compensation Committee and then calculating the Black-Scholes value of the shares eliminated from the option awards and dividing that quotient by a 30-day average of the equity value of our common stock.

In the case of our management team, the Compensation Committee makes awards of stock options, and most recently restricted stock units, in line with awards to our other employees described above, as well as performance share units. Currently, the performance share units are divided into two types: one half are performance share units, or PSUs, which are tied to corporate research and development objectives, and one half are relative total stockholder return units, or rTSRUs, which are tied to our relative stock performance. Specifically, the PSUs are subject to research and development goals based on advancement of our clinical programs in respiratory syncytial virus (RSV), SARS-CoV-2, hepatitis B virus (HBV) and human metapneumovirus (hMPV) and our other earlier stage research over a two-year period; and the rTSRUs are based on the relative performance of our common stock price against the other component companies in the Nasdaq Biotechnology Index over the same 60-day calendar periods two years apart, with no units vesting unless (i) our stock is in at least the 65th percentile of component companies at the end of the performance period and (ii) there is an absolute increase in our stock value over the performance period, with the target number of shares vesting only if the performance of our stock is in the 75th percentile when compared to the stock price performance of those component companies. Each type of performance share unit can expire unvested or vest in an amount up to 150% of the target number of units, depending on the company's performance.

Our Compensation Committee believes that the program of stock options, restricted stock units and performance units provides management and our employees appropriate incentives to build the value of our company.

We Have Managed Our Equity Burn Rate Efficiently, Averaging 3.97% Per Year

In determining the proposed number of shares to be added to the reserve for issuance under the 2019 Equity Plan and for which stockholder approval is being sought, the Compensation Committee considered the historical amounts of common stock underlying equity awards granted by the Company in the past three years and our projections for the coming year based on the Company's current employee headcount and projected additions. In our fiscal years 2020, 2021 and 2022, the Company made equity awards, including a targeted number of shares reserved for performance-based unit awards, representing a total of 875,084, 1,192,463 and 1,123,056 shares, respectively, without giving effect to any forfeitures.

The following table sets forth information regarding historical awards granted for the 2020 through 2022 fiscal periods, and the corresponding annual net burn rate, which is defined as the number of shares covered by awards granted, net of forfeitures, divided by the weighted-average number of shares of common stock outstanding for that year, for each of the last three fiscal years:

<u>Share Element</u>	<u>Fiscal Year Ended September 30,</u>		
	<u>2022</u>	<u>2021</u>	<u>2020</u>
Time-based Stock Options and Restricted Stock Units Granted, Net of Forfeitures	788,161	834,833	619,832
Performance-Based Full Value Unit Awards Granted, at Target, Net of Forfeitures	2,342	131,580	33,456
Total Time-Based Awards Granted and Performance-Based Awards Granted	790,503	966,413	653,288
Weighted-Average Common Shares Outstanding During the Fiscal Year	20,603,312	20,171,425	19,940,376
Annual Net Burn Rate	3.80%	4.80%	3.30%
3-Year Average Net Burn Rate	3.97%		

Without deducting forfeitures, our three-year average burn rate for the 2020-2022 fiscal years was 5.25%. This compares to a median burn rate of 4.50% in our peer group in calendar year 2021, the most recent year for which comparable data is available.

Our Equity Award Overhang Reflects 9+ Years Without Dilutive Equity Financings

In making its determinations, the Compensation Committee also considered the total number of shares reserved for outstanding stock options and other equity awards. As of December 31, 2022, we had shares reserved for outstanding equity awards covering a total of 5,251,871 shares, consisting of stock options to purchase a total of 4,510,600 shares, restricted stock units for 439,141 shares, and performance unit awards targeting a total of 302,130 shares, with 560,008 shares remaining reserved for future issuance. Our overhang reflects the fact that we have not issued any shares of our common stock in an equity financing since the closing of our initial public offering in March 2013. Most biotechnology companies in that period of time would have done several rounds of follow-on equity financings, substantially reducing the percentage of shares represented by outstanding equity awards. In Enanta's case, this dilution was avoided because we have received over \$1 billion in milestone payments and royalties on sales of products containing our HCV protease inhibitors since our 2013 IPO, and we had \$278.5 million in our cash and cash equivalent reserves at September 30, 2022.

The Proposed Increase Is Projected to Enable Needed Recruitment and Retention into 2024

After a review of our historical practices and in the context of our current and expected future growth, the Compensation Committee has determined that the proposed increase of 975,000 shares, which represents the equivalent of 4.68% of our shares of common stock outstanding as of December 31, 2022, is appropriate to cover our anticipated requirements for recruitment of new employees and retention of our personnel until at least the 2024 annual meeting of stockholders. The proposed increase is made in the context of our need to recruit more employees primarily in support of our research and the advancement of our clinical-stage pipeline into larger clinical trials. The Compensation Committee believes that the proposed addition to the share reserve is essential to the Company's ability to continue to grant equity incentives for at least the next year, which is vital to our efforts to attract and retain the highly skilled individuals required to support our continued growth in the extremely competitive labor markets in which we compete.

The closing price of our common stock on the Nasdaq Global Select Market on December 31, 2022, was \$46.52 per share. Based solely on the closing price of our common stock on December 31, 2021, the aggregate intrinsic value of the proposed additional 975,000 shares of common stock, which would be newly reserved for issuance under the 2019 Equity Plan, is \$ 45,357,000.

Stockholder Approval Requirements

Approval of the proposed amendment to the 2019 Equity Plan by our stockholders is required under the listing rules of the Nasdaq Stock Market. Stockholder approval will also ensure favorable federal income tax treatment for awards of incentive stock options, if any, that may be made under Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

General Description of 2019 Equity Plan

The purpose of the 2019 Equity Plan is to attract and retain employees, directors and consultants and to provide an incentive for these individuals to achieve long-range performance goals. The 2019 Equity Plan permits us, under the direction of the Compensation Committee, to grant equity awards to our employees, directors and consultants, including incentive and non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based and cash-based awards. Under the 2019 Equity Plan to date, we have awarded only non-statutory stock options, time-based restricted stock units, performance share units and relative total stockholder return units.

As of December 31, 2022, 167 employees and six non-employee directors were eligible to participate in the 2019 Equity Plan. As of that date, a total of 2,842,785 shares were reserved under the 2019 Equity Plan for outstanding stock options, and 439,141 shares were reserved for outstanding restricted stock unit awards. In addition, as of that date a total of 302,130 shares were reserved for potential issuance pursuant to performance-based and market-based stock unit awards at the target amounts of such awards. While no further awards have been made under our 2012 Equity Incentive Plan, referred to as our 2012 Equity Plan, since February 26, 2019, shares subject to options that were granted under that plan and that are forfeited or that expire unexercised are then added to the shares available for issuance under the 2019 Equity Plan. Similarly, no further awards were made under our Amended and Restated 1995 Equity Incentive Plan, referred to as the 1995 Equity Plan, after our initial public offering in March 2013, and shares subject to options that were granted under that plan and that are forfeited or that expire unexercised are then added to the shares available for issuance under the 2019 Equity Plan. There remain 1,606,926 shares subject to outstanding options awarded under the 2012 Equity Plan and 60,889 shares subject to outstanding options awarded under the 1995 Equity Plan, all of which, if forfeited, would become available for issuance under the 2019 Equity Plan. In aggregate, as of December 31, 2022 we had 5,811,871 shares subject to outstanding options and equity awards under all three of our equity incentive plans or reserved for future issuance under the 2019 Equity Plan.

As of December 31, 2022, outstanding options awarded under the 2019 Equity Plan had exercise prices ranging from \$39.70 per share to \$102.54 per share. The weighted average exercise price of all outstanding options under the plan and its predecessors is \$56.76 per share, and those options have a term of ten years and, as of December 31, 2022, had a weighted average duration of 8.43 years. As the amount of any awards under the 2019 Equity Plan is within the Compensation Committee’s discretion, total awards that may be granted for a fiscal year are not determinable until completion of the year.

The following table sets forth shares underlying awards granted under the 2019 Equity Plan and unexercised or not settled, as the case may be, as of the close of business on September 30, 2022:

Total Awards Under the 2019 Equity Incentive Plan	
	Number of Shares of Common Stock Underlying Options/Units[†]
Current named executive officers:	
Jay R. Luly, Ph.D.	430,575 ^(a)
Scott T. Rottinghaus, M.D.	101,440 ^(b)
Yat Sun Or, Ph.D.	131,400 ^(c)
Nathaniel S. Gardiner, J.D.	128,500 ^(d)
Paul J. Mellett	128,500 ^(e)
Current executive officers as a group (7 persons)	1,183,805 ^(f)
Current non-executive officer directors as a group (6 persons)	172,644
Other Enanta employees as a group	1,300,205
Total Awards through September 30, 2022	2,656,654 ^(f)

† The numbers of performance-based PSU and rTSRU unit awards included in this table are the target numbers of shares subject to the awards. Actual performance may result in no shares being issued under a stock unit award or up to 1.5x that target number of shares being issued. Restricted stock units with time-based vesting are included at the total number of shares subject to the awards.

- (a) Includes a total of 59,400 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.
- (b) Includes a total of 6,440 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.

- (c) Includes a total of 29,700 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.
- (d) Includes a total of 26,800 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.
- (e) Includes a total of 26,800 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.
- (f) Includes a total of 149,140 shares subject to performance-based unit awards, which will only vest upon achievement of specified performance criteria over the corresponding performance period.

Because the granting of awards under the 2019 Equity Plan is discretionary, we cannot now determine the number or type of awards to be granted in the future to any particular person or group if the amendment to the 2019 Equity Plan is approved.

Administration and Eligibility

Awards are made by the Compensation Committee, which has been designated by our Board of Directors to administer the 2019 Equity Plan. Subject to certain limitations, the Compensation Committee may delegate to one or more of our executive officers the power to make awards to participants who are not subject to Section 16 of the Securities Exchange Act of 1934 and are not “executive officers” for purposes of the Securities Exchange Act of 1934, as amended. The Compensation Committee has authorized our Chief Executive Officer to make awards to non-executive employees within parameters approved by the Committee.

The Compensation Committee administers the 2019 Equity Plan and determines the terms and conditions of each equity award to our executive officers and directors, including the number of shares subject to the award, the exercise price and the form of payment of the exercise price for any stock option, the vesting conditions of the award and the terms of any withholding of shares or other provisions to satisfy tax withholding requirements for the award.

Types of Awards

The 2019 Equity Plan provides for the following categories of awards:

Stock Options. The Compensation Committee may grant options to purchase shares of common stock that are either incentive stock options, or ISOs, eligible for the special tax treatment described below, or nonstatutory stock options. No option may have an exercise price that is less than the fair market value of the common stock on the date of grant or a term of more than ten years. An option may be exercised by the payment of the option price in cash or with such other lawful consideration as the Compensation Committee may determine, including by delivery of shares of common stock owned by the optionholder, by a broker-assisted cashless exercise, or by Enanta retaining shares otherwise issuable pursuant to the option.

Restricted Stock. Our Compensation Committee may grant shares of common stock that are only earned if specified conditions, such as a completing a term of employment or satisfying pre-established performance goals, are met and that are otherwise subject to forfeiture. Shares of restricted stock may not be sold, transferred or otherwise encumbered until earned, unless the Compensation Committee provides otherwise.

Restricted Stock Units. Our Compensation Committee may grant units that represent the right to receive shares of our common stock, subject to such terms, restrictions, conditions, performance criteria, vesting requirements, settlement terms, and payment rules, if any, as the Committee shall determine.

Unrestricted Stock. Our Compensation Committee may grant shares of common stock that are not subject to restrictions or forfeiture.

Stock Appreciation Rights. Our Compensation Committee may grant stock appreciation rights, or SARs, where the participant receives cash, shares of common stock, or other property, or a combination thereof, as determined by the Compensation Committee, equal in value to the difference between the measurement price of the SAR and the fair market value of the common stock on the date of exercise. SARs may be granted in tandem with options (at or after award of the option) or alone and unrelated to an option. SARs in tandem with an option shall terminate to the extent that the related option is exercised, and the related option shall terminate to the extent that the tandem SARs are exercised. SARs granted in tandem with options shall have a measurement price not less than the exercise price of the related option. SARs granted alone and unrelated to an option shall have a measurement price not less than 100% of the Fair Market Value of the common stock on the date of award or on such future date as the Committee may determine is the grant date of such award.

Federal Income Tax Consequences Relating to Awards

Incentive Stock Options. An optionee does not realize taxable income upon the grant or exercise of an incentive stock option, known as an ISO, under the 2019 Equity Plan. If no disposition of shares issued to an optionee pursuant to the exercise of an ISO is made by the optionee within two years from the date of grant or within one year from the date of exercise, then (a) upon sale of such shares, any amount realized in excess of the option price (the amount paid for the shares) is taxed to the optionee as a long-term capital gain and any loss sustained will be a long-term capital loss and (b) no deduction is allowed to Enanta for Federal income tax purposes. The exercise of ISOs gives rise to an adjustment in computing alternative minimum taxable income that may result in alternative minimum tax liability for the optionee.

If shares of common stock acquired upon the exercise of an ISO are disposed of prior to the expiration of the two-year and one-year holding periods described above, referred to as a disqualifying disposition, then (a) the optionee realizes ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares at exercise (or, if less, the amount realized on a sale of such shares) over the option price thereof and (b) Enanta is entitled to deduct this amount. Any further gain realized is taxed as a capital gain, which will be long-term if the shares were held for more than one year following exercise and does not result in any deduction to Enanta. A disqualifying disposition in the year of exercise will generally avoid the alternative minimum tax consequences of the exercise of an ISO.

Non-statutory Stock Options. No income is realized by the optionee at the time a non-statutory option is granted. Upon exercise, (a) ordinary income is realized by the optionee in an amount equal to the difference between the option price and the fair market value of the shares on the date of exercise and (b) Enanta receives a tax deduction for the same amount. Upon disposition of the shares, appreciation or depreciation after the date of exercise is treated as a capital gain or loss, which will be short-term or long-term depending upon how long the shares have been held and will not result in any deduction by Enanta.

Restricted Stock. Awards of restricted stock that are non-transferable and subject to forfeiture are generally not taxable to the recipient until the shares vest. When the shares vest, the recipient realizes compensation income equal to the difference between the amount paid for the shares and their fair market value at the time of the vesting, and we are entitled to a corresponding deduction. The tax is payable for the year in which the vesting occurs, regardless of whether the shares are sold at that time. Upon subsequent disposition of the shares, any appreciation or depreciation is treated as short-term or long-term capital gain or loss, depending on the length of time the recipient has held the shares after the date on which the shares vested.

Instead of being taxed when the shares vest, a recipient may elect to be taxed in the year the shares are awarded by filing a "Section 83(b) election" with the Internal Revenue Service within 30 days after issuance of the restricted shares. The recipient then realizes compensation income in the year of the award equal to the difference between the amount paid for the shares and their fair market value at the time of issuance, and Enanta is entitled to a corresponding deduction at that time. Upon subsequent disposition of the shares, any appreciation or depreciation is treated as short-term or long-term capital gain or loss, depending on the length of time the recipient has held the shares since the date of receipt of the shares.

Unrestricted Stock. Generally, a recipient will be taxed at the time of the grant of the award. The fair market value of the shares at that time will be treated as ordinary income and Enanta is entitled to receive a tax deduction for the amount reported as ordinary income. Upon disposition of the shares, any appreciation or depreciation since the time of grant is treated as short-term or long-term capital gain or loss, depending on the length of time the recipient has held the shares.

Restricted Stock Units. A recipient does not realize taxable income upon the grant or vesting of a restricted stock unit. When a stock unit is settled, i.e. when the underlying share of common stock is issued to the recipient, the recipient realizes ordinary income in an amount equal to the fair market value of the shares distributed to settle the award, and Enanta is entitled to a tax deduction for such amount. If the award is settled in shares, then upon disposition of the shares any subsequent appreciation or depreciation is treated as short- or long-term capital gain or loss, depending on the length of time the recipient has held the shares since the date of settlement.

Internal Revenue Code Section 162(m) Limitation on Deductibility of Certain Equity Awards

After enactment of the Tax Cuts and Jobs Act of 2017, United States tax law generally does not allow publicly-held companies to obtain tax deductions for compensation of more than \$1.0 million paid in any year to any of the chief executive officer, the chief financial officer and the next three highest paid executive officers, as well as any officer who was treated as a covered employee under Section 162(m) of the U.S. Internal Revenue Code of 1986, as amended, for any year beginning after December 31, 2016 (each, a “covered employee”). As a result, Enanta is not entitled to a compensation deduction with respect to awards under the 2019 Equity Plan to a covered employee to the extent the aggregate amount payable results in total compensation in excess of the \$1.0 million limit.

Equity Compensation Plan Information

The following table provides information about the securities authorized for issuance under the Company’s equity compensation plans as of September 30, 2022:

Equity Compensation Plan Information			
Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(a)	(b)	(c)
Equity compensation plans approved by security holders ⁽¹⁾	4,413,846 ⁽²⁾	\$48.46	1,549,019 ⁽³⁾⁽⁴⁾
Equity compensation plans not approved by security holders			
Totals	4,413,846		1,549,019

- (1) Consists of the 2019 Equity Plan, the 2012 Equity Plan, the 1995 Equity Plan and our Employee Stock Purchase Plan.
- (2) Consists of shares of our common stock issuable upon exercise of outstanding options, restricted stock units and performance share units issued under the 2019 Equity Plan, the 2012 Equity Plan and the 1995 Equity Plan.
- (3) Consists of 1,363,019 shares of our common stock reserved for future issuance under the 2019 Equity Plan and 186,000 shares reserved for issuance under our Employee Stock Purchase Plan.

- (4) As of December 31, 2022, after annual equity awards in the quarter then ended, only 560,008 shares of our common stock remained available for future issuance under the 2019 Equity Incentive Plan.

New Plan Benefits Table

The issuance of any awards under the 2019 Equity Plan will be at the discretion of our Compensation Committee. Therefore, it is not possible to determine the amount or form of any award that will be granted to any individual in the future.

Proposed Approval of Additional Shares to be Reserved for Issuance under the 2019 Equity Plan

We are seeking stockholder approval of the increase in the number of shares of our common stock reserved for issuance under the 2019 Equity Plan by 975,000 shares. If Proposal 2 is approved by the requisite vote of stockholders, the Company intends to register subsequently the additional shares reserved for issuance under the 2019 Equity Incentive Plan by filing a registration statement on Form S-8.

The preceding summary of the 2019 Equity Plan is qualified in its entirety by reference to the full text of the 2019 Equity Plan, which is set forth as Appendix A to this proxy statement filed with the SEC.

Vote Required

The affirmative vote of a majority of the shares represented in person or by proxy at the annual meeting and voted on this proposal will constitute the approval of the amendment to increase the number of shares of our common stock reserved for issuance under our 2019 Equity Plan by 975,000 shares. Abstentions and broker non-votes will not be treated as votes cast for the purpose of determining the outcome of this proposal.

Recommendation

We recommend a vote “FOR” the proposal to approve the amendment to the 2019 Equity Incentive Plan.

PROPOSAL 3

ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO

OUR NAMED EXECUTIVE OFFICERS

In accordance with the requirements of Section 14A of the Exchange Act and the related rules of the SEC, we are providing our stockholders with the opportunity to cast an advisory (non-binding) vote on executive compensation, also known as a “say-on-pay” vote. In light of the vote of our stockholders recommending annual say-on-pay votes at our 2020 annual meeting of stockholders, we intend to continue to seek this input on an annual basis.

The say-on-pay vote is a non-binding vote on the compensation paid to our named executive officers, as described elsewhere in this proxy statement under the heading “*Executive Compensation*,” and includes the “Compensation Discussion and Analysis,” the tabular disclosure regarding compensation of our named executive officers and the accompanying narrative disclosure set forth elsewhere in this proxy statement. The Executive Compensation section describes our compensation philosophy and objectives, how we determine executive compensation, the elements of total compensation and the actual compensation of our named executive officers identified in that section. Our Compensation Committee and our Board believe that the policies and practices described in the “Compensation Discussion and Analysis” are effective in implementing our compensation philosophy and objectives and that the compensation of our named executive officers for 2022 reflects and supports those policies and practices.

The say-on-pay vote is not binding on our Compensation Committee or our Board. However, our Compensation Committee and the Board will take into account the result of the vote when determining future executive compensation arrangements.

Recommendation

We recommend a vote “FOR” the proposal to approve, on an advisory basis, the compensation paid to our named executive officers, as described in this proxy statement.

PROPOSAL 4

RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The firm of PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited our financial statements for each of the years ended September 30, 2022, 2021 and 2020. Our Audit Committee has appointed them to serve as our auditors for the fiscal year ending September 30, 2023. Detailed disclosure of the audit and tax fees we paid to PricewaterhouseCoopers LLP in 2022 and 2021 may be found in the “Audit Fees” section of this proxy statement. Based on these disclosures and information in the Audit Committee Report provided elsewhere in this proxy statement, our Audit Committee is satisfied that PricewaterhouseCoopers LLP is sufficiently independent of management to perform its duties properly. Although not legally required to do so, our Board considers it desirable to seek, and recommends, stockholder ratification of our selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year 2023. If the stockholders fail to ratify our selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee determines that such a change would be in the best interest of Enanta and its stockholders.

Recommendation

We recommend a vote “FOR” ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm.

CORPORATE GOVERNANCE

Board and Committee Matters

Board Leadership and Independence. Our Board of Directors has determined that Bruce L.A. Carter, Ph.D. as well as five of the other directors continuing their terms after the 2023 Annual Meeting, are independent directors as defined by applicable Nasdaq Stock Market standards governing the independence of directors. Jay R. Luly, Ph.D., our President and Chief Executive Officer, is not considered independent.

The Board of Directors sets company strategy and provides oversight and accountability for our Chief Executive Officer and management. Dr. Carter has served as our non-executive Chairman of the Board since December 2015. Dr. Carter presides over meetings of the Board of Directors and provides guidance to our Chief Executive Officer. Dr. Luly is responsible for setting the strategic direction for our Company and the day-to-day leadership and performance of the Company. We believe that separation of our Board of Directors and executive leadership preserves the independence of these roles and maximizes performance.

Board Meetings and Committees. Our Board of Directors held eight meetings during 2022, and the independent directors held executive sessions at four of the meetings of the Board. During 2022, each of the directors then in office attended at least 75% of the aggregate of all meetings of the Board of Directors and all meetings of the committees of the Board of Directors on which such director then served.

Continuing directors and nominees for election as directors in a given year are required to attend the annual meeting of stockholders, barring significant commitments or special circumstances. All of our directors then serving as directors attended our 2022 annual meeting of stockholders.

Stockholder Communications. Any stockholder wishing to communicate with our Board of Directors, a particular director or the chair of any committee of the Board of Directors may do so by sending written correspondence to our principal executive offices, to the attention of the Chairman of the Board. All such communications will be delivered to the Board of Directors or the applicable director or committee chair.

During 2022, our Board of Directors had three standing committees: Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. The following matrix shows the composition and leadership of each of these standing committees:

Committee	Board Committees						
	Carter	Foletta	Hata	Luly	Peterson	Russell	Vance
Audit		✓ Chair				✓	✓
Compensation	✓		✓		✓ Chair		✓
Nominating and Corporate Governance . . .	✓	✓	✓		✓	✓	✓ Chair

Audit Committee. Our Audit Committee’s responsibilities include:

- appointing, approving the compensation of and assessing the independence of our registered public accounting firm;
- overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;
- reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures;

- monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;
- overseeing our risk assessment and risk management policies;
- establishing policies regarding hiring employees from the registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;
- meeting independently with our registered public accounting firm and with our management;
- reviewing and approving or ratifying any related person transactions; and
- preparing the Audit Committee Report required by SEC rules.

The members of our Audit Committee during 2022 were Messrs. Foletta and Vance and Dr. Russell, with Mr. Foletta serving as Chair of the Audit Committee. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our Board has determined that each of Messrs. Foletta and Vance is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Our Board has determined that each of Messrs. Foletta and Vance and Dr. Russell is independent under the applicable rules of Nasdaq and under the applicable rules of the SEC. The Audit Committee held five meetings during 2022. The Audit Committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq. A copy of the Audit Committee charter is available in the “Investors – Corporate Governance” section of the Company’s website at www.enanta.com.

Compensation Committee. Our Compensation Committee’s responsibilities include:

- annually reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer;
- reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief executive officer and our other executive officers;
- overseeing an evaluation of our senior executives;
- overseeing and administering our cash and equity incentive plans;
- reviewing and making recommendations to our board of directors with respect to director compensation; and
- reviewing and discussing annually with management our executive compensation disclosure, and our Compensation Committee Report, required by SEC rules.

The members of our Compensation Committee during 2022 were Ms. Peterson, Dr. Carter, Mr. Hata and Mr. Vance. Ms. Peterson serves as Chair our Compensation Committee. None of the members of our Compensation Committee has been one of our officers or employees, other than Mr. Hata who was a business development executive at Enanta before 2011. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the Board or Compensation Committee of any entity that has one or more executive officers on our Board or Compensation Committee. Each of the members of our Compensation Committee is independent under the applicable rules and regulations of Nasdaq and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. Our Compensation Committee held twelve meetings during 2022. Our Compensation Committee operates under a written charter adopted by the Board, which is available in the “Investors – Corporate Governance” section of our website at www.enanta.com.

For more information regarding the authority of our Compensation Committee, the extent of delegation to our Compensation Committee, our processes and procedures for determining executive compensation and the role of executive officers and compensation consultants in determining or recommending the amount or form of compensation for directors and executive officers, please see “Executive Compensation – Compensation Discussion and Analysis” in this proxy statement.

Nominating and Corporate Governance Committee. Our Nominating and Corporate Governance Committee's responsibilities include:

- identifying individuals qualified to become members of our board of directors;
- recommending to our board of directors the persons to be nominated for election as directors and to each of our board's committees;
- reviewing and making recommendations to our board of directors with respect to our board leadership structure;
- reviewing and making recommendations to our board of directors with respect to management succession planning;
- developing and recommending to our board corporate governance principles; and
- overseeing an annual self-evaluation by our board of directors.

The current members of our Nominating and Corporate Governance Committee are our independent directors, namely Drs. Carter and Russell, Messrs. Foletta, Hata and Vance and Ms. Peterson. Mr. Vance chairs the Nominating and Corporate Governance Committee. Each of the members of our Nominating and Corporate Governance Committee is an independent director under the applicable rules and regulations of Nasdaq relating to Nominating and Corporate Governance Committee independence. The Committee held one meeting during 2022. The Nominating and Corporate Governance Committee operates pursuant to a written charter, which is available in the "Investors – Corporate Governance" section of our website at www.enanta.com.

The Nominating and Corporate Governance Committee considers candidates for Board membership suggested by its members and the Chief Executive Officer. It typically establishes a subcommittee (the "Recruiting Subcommittee") to work with an independent recruiting firm and Dr. Luly to help identify and recruit additional candidates. This was the process that resulted in the recruitment of Drs. Carter and Russell, Messrs. Foletta and Hata and Ms. Peterson. Additionally, in selecting nominees for directors, the Nominating and Corporate Governance Committee will review candidates recommended by stockholders in the same manner and using the same general criteria as candidates recruited by the committee and/or recommended by the Board. Any stockholder who wishes to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described later in this proxy statement under the heading "Stockholder Matters – Stockholder Recommendations for Director Nominations." The Recruiting Subcommittee will also consider whether to nominate any person proposed by a stockholder in accordance with the provisions of our bylaws relating to stockholder nominations as described later in this proxy statement under the heading "Stockholder Matters – Deadline for Stockholder Proposals and Director Nominations."

This process used by the Recruiting Subcommittee in recent years is likely to be the process for any future director searches. Typically, the Recruiting Subcommittee starts the director search process by identifying a mix of types of experience and personal characteristics that the Recruiting Subcommittee considers most valuable to complement the skills and experience of existing directors. Once the Recruiting Subcommittee has identified prospective nominee candidates, the Recruiting Subcommittee then makes an initial determination as to whether to conduct a full evaluation of any candidate. This initial determination is based on the information provided to the Recruiting Subcommittee in a report from the recruiting firm, as well as the Recruiting Subcommittee's own knowledge of the prospective candidate. The preliminary determinations are based primarily on the need for additional Board members to fill vacancies or expand the size of the Board and the likelihood that the prospective nominee could satisfy the evaluation factors described below. The Recruiting Subcommittee then evaluates the prospective nominees against the standards and qualifications set out in our Corporate Governance Guidelines, which include among others:

- the extent to which the prospective nominee's skills, experience and perspective add to the range of talent appropriate for the Board and whether such attributes are relevant to our business and industry;
- the prospective nominee's ability to dedicate the time and resources sufficient for the diligent performance of Board duties;

- whether the prospective nominee meets the independence requirements and Audit Committee and Compensation Committee qualifications defined under applicable Nasdaq Stock Market standards and if appropriate, the Audit Committee financial expert requirements defined under applicable SEC rules and regulations; and
- the extent to which the prospective nominee holds any position that would conflict with a director's responsibilities to Enanta.

The Committee seeks a variety of occupational and personal backgrounds on the Board in order to obtain a range of viewpoints, perspectives and skills.

If the Recruiting Subcommittee's initial evaluation is positive, the members of the Recruiting Subcommittee each interview the candidate. Upon completion of this evaluation and interview process, the Recruiting Subcommittee confers informally and then makes a recommendation to the full Board as to whether the candidate should be nominated by the Board and invites other directors to interview the candidate in person or by phone. The Board then determines whether to approve the nominee after considering the recommendation and report of the Chair of the Recruiting Subcommittee.

In November 2022, the Nominating and Corporate Governance Committee established a subcommittee (the "Nominating Subcommittee") for the purpose of determining the director nominees for election at the 2023 Annual Meeting. The Nominating Subcommittee consists of Mr. Vance, Ms. Peterson, Dr. Russell and Messrs. Foletta and Hata, all of whom are independent directors. In January 2023, the Nominating Subcommittee approved the director nominees for election at the 2023 Annual Meeting.

Risk Oversight. The Board's role in our risk oversight process includes receiving reports from time to time from the Audit Committee on areas of material risk to the Company, including operational, financial, legal and regulatory, and strategic and reputational risks.

Certain Relationships and Related Transactions

Policy on Related Person Transactions

Our Board of Directors has adopted a written Policy on Related Person Transactions that sets forth our policies and procedures for the reporting, review, and approval or ratification of each related person transaction. Our Audit Committee is responsible for implementing this policy and determining that any related person transaction is in our best interests. The policy applies to transactions and other relationships that would need to be disclosed in this proxy statement as related person transactions pursuant to SEC rules. In general, these transactions and relationships are defined as those involving a direct or indirect interest of any of our executive officers, directors, nominees for director and 5% stockholders, as well as specified members of the family or household of any of these individuals or stockholders, where we or any of our affiliates have participated in the transaction (either as a direct party or by arranging the transaction) and the transaction involves more than \$120,000. In adopting this policy, our Board expressly excluded from its coverage any transactions, among others, involving compensation of our executive officers or directors that it or our Compensation Committee has expressly approved.

We have not engaged in any transactions with related persons since the beginning of our 2022 fiscal year.

Compensation Committee Interlocks and Insider Participation

During 2022, our Compensation Committee members were Ms. Peterson, Dr. Carter and Messrs. Hata and Vance, none of whom currently is, or formerly was, an officer or employee of Enanta, other than Mr. Hata who was a business development executive of Enanta before 2011. None of our executive officers served as a member of the board of directors or compensation committee of any other company that had one or more executive officers serving as a member of our Board of Directors or Compensation Committee.

EXECUTIVE OFFICERS

The following section provides biographical information as of December 15, 2022, about our current executive officers:

<u>Name</u>	<u>Age</u>	<u>Position</u>
Jay R. Luly, Ph.D.	66	President and Chief Executive Officer
Paul J. Mellett	67	Senior Vice President, Finance & Administration and Chief Financial Officer
Yat Sun Or, Ph.D.	71	Senior Vice President, Research & Development and Chief Scientific Officer
Scott T. Rottinghaus, M.D.	49	Senior Vice President and Chief Medical Officer
Nathaniel S. Gardiner, J.D.	69	Senior Vice President and General Counsel
Tara L. Kieffer, Ph.D.	45	Senior Vice President, New Product Strategy and Development
Brendan Luu	48	Senior Vice President, Business Development

Jay R. Luly, Ph.D., has served as our President and Chief Executive Officer and as a member of our board of directors since July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois at Urbana-Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley.

Paul J. Mellett has served as our Senior Vice President, Finance & Administration and Chief Financial Officer since September 2003. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics, Inc., a public biotechnology company. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989. Mr. Mellett received a B.S. in Business Administration from Boston College.

Yat Sun Or, Ph.D., has been our Senior Vice President, Research & Development and Chief Scientific Officer since November 1999. Prior to joining Enanta, Dr. Or held key leadership positions at Abbott Laboratories from 1985 to 1999, where he received two Chairman’s Awards for his outstanding research, which led to the discovery and development of immunosuppressant and antibacterial drugs. Prior to Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.

Scott T. Rottinghaus, M.D., has been our Senior Vice President and Chief Medical Officer since August 2022. Prior to joining Enanta, Dr. Rottinghaus was in clinical development at Alexion, a global biopharmaceutical company, since 2015, most recently as Vice President and Head of Clinical Development for Hematology and Nephrology of Alexion (subsequently Alexion AstraZeneca Rare Disease) from March 2019 to August 2022, where he led development for several clinical assets, including ravulizumab. Previously, Dr. Rottinghaus was in clinical development at Pfizer Inc., a global pharmaceutical company, from 2007 to 2015, most recently as

Senior Director and a Global Clinical Lead. Dr. Rottinghaus also served as an Assistant Clinical Professor of Medicine (2017-2019) and a Clinical Instructor of Medicine (2008-2017) at Yale School of Medicine, teaching residents and fellows on the infectious diseases consult service. Dr. Rottinghaus received a Doctorate in Medicine from Mayo Medical School after earning an M.Sc. (Biology) from University of Cambridge and a B.A. (Classics) and B.S. (Biology) from Kansas State University.

Nathaniel S. Gardiner, J.D., has served as our Senior Vice President and General Counsel since May 2014 and has served as our Secretary since 1995. Previously Mr. Gardiner was a corporate and securities law partner for 25 years, most recently at Edwards Wildman Palmer LLP since October 2011, previously at Edwards Angell Palmer & Dodge LLP since November 2005, and before that at Palmer & Dodge LLP, where he represented Enanta and several other biotechnology companies. Mr. Gardiner received his A.B. from Harvard College and his J.D. from the University of Virginia School of Law.

Tara L. Kieffer, Ph.D., joined us as Senior Vice President, New Product Strategy and Development in December 2020. Previously Dr. Kieffer held positions of increasing responsibility at Vertex Pharmaceuticals Incorporated, a biotechnology company, most recently as Vice President, External Innovation, Business Development since October 2018. Prior to that she was Vice President, Integrated Program Management since March 2017, and Senior Director, Chief of Staff to the Chief Medical Officer from October 2014 to March 2017. In her previous ten years at Vertex she advanced as a virologist, becoming Director, Clinical Biomarkers in the Department of Translational Medical Sciences. Dr. Kieffer did her graduate work at Johns Hopkins School of Medicine, Department of Molecular Biology and Genetics from 1999 to 2004. Dr. Kieffer received her B.A. from Colgate University and received her Ph.D. in Immunology from Johns Hopkins University School of Medicine.

Brendan Luu joined us as Senior Vice President, Business Development in January 2021. During the prior 17 years Mr. Luu held business development positions of increasing responsibility at Merck KGaA, a pharmaceutical company, most recently as Vice President and Global Head of Oncology Business Development since 2018. Previously Mr. Luu was Senior Director and Global Head of Business Development, Strategic Initiatives where he led strategy and partnering efforts for Merck KGaA's late-stage pipeline. Earlier in his career Mr. Luu held various roles with BASF Corporation and Tyco International, working in engineering, sales and marketing. Mr. Luu his B.A. from Drexel University and received his M.B.A. from the New York University Stern School of Business.

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This section provides an overview and analysis of our executive compensation program, including its design and objectives, as well as the rationale applied and the decisions made under our program with respect to the compensation paid or awarded in fiscal 2022 to Drs. Luly, Rottinghaus and Or and Messrs. Gardiner and Mellett, whom we refer to collectively as our Named Executive Officers, or NEOs. Later in this proxy statement, you will find a series of tables containing specific information about the compensation earned by these individuals in fiscal 2022. The discussion below is intended to help you understand the detailed information provided in those tables and to put that information into context based on our overall compensation program for our Named Executive Officers.

Our Executive Compensation Philosophy

We rely on the expertise of our executive management team to drive overall company performance. Our compensation program is intended to align the interests of our Named Executive Officers with those of our stockholders by measuring and rewarding their performance against our research and development objectives. Consistent with this pay-for-performance philosophy, our Compensation Committee has structured certain elements of the compensation program for our executive officers, including our NEOs, to reward performance by emphasizing equity compensation opportunities, as well as variable cash incentives that are based on corporate performance measured against annual objectives that are pre-established by our Compensation Committee. In addition, a significant component of the executive equity compensation program is based on corporate performance against two-year research and development and business development objectives and relative total stockholder return.

Our Compensation Committee has determined that our executive compensation program will generally over time target the executive team's base salaries, total target cash compensation and time-based equity awards to those of executives in the 50th percentile of comparable executives in our peer group companies. In addition, our Compensation Committee has expanded our executive team's total equity compensation opportunity by including performance awards that vest in part only if Enanta achieves high levels of performance against the company's longer-term research and development objectives and in part if the value of Enanta's stock increases and if the percentage increase in Enanta's stock price is more than the percentage increases of at least 65% of the traded stocks of other public biotechnology companies in the Nasdaq Biotechnology Index.

Our compensation philosophy is designed to promote our corporate objectives. Our guiding principles focus on:

- Attracting, retaining and motivating top talent;
- Aligning executive compensation with the attainment of our research and development objectives and business strategy;
- Rewarding executives for achievement of near and long-term individual and corporate goals; and
- Aligning executive compensation with long-term stockholder value and accomplishments that we believe will increase the value of Enanta in the long term.

Compensation Committee

Our board of directors has delegated authority to our Compensation Committee, which currently consists of four of our six non-employee directors, to provide oversight of our executive compensation program for our NEOs as well as our other executive officers. Our Compensation Committee reviews and evaluates the executive compensation program on an annual basis to ensure that the program is aligned with our compensation philosophy.

Since our compensation program is administered on a calendar year basis, our Compensation Committee at its regularly scheduled November meeting reviews our corporate performance for the year and takes the following actions:

- (i) determines annual variable cash compensation;
- (ii) sets base salary and target percentages of base salary for variable cash compensation for the calendar year beginning January 1;
- (iii) grants time-based equity awards; and
- (iv) determines the number of shares that will be subject to performance unit awards.

Our Compensation Committee reviews these actions with the other non-employee directors for their input before finalizing them. In addition, our Compensation Committee makes recommendations to our Board of Directors, based on recommendations made by our compensation consultant, regarding non-employee director fees and equity awards.

Role of Compensation Consultant

Our Compensation Committee retains each year an independent compensation consulting firm to provide advisory services concerning our compensation programs for our executive officers. This consulting firm also reviews the fees and equity awards for non-employee directors. These services include recommendations regarding our compensation practices and, based on direction from our Compensation Committee, detailed analyses and recommendations based on the percentile rankings of comparable executives, as well as non-employee directors, in our peer group companies.

Radford Consulting, an AON Consulting company, which we refer to as Radford, was selected by our Compensation Committee for this role and assisted the committee by providing the following services in fiscal 2022:

- Competitive benchmarking and market data analysis, including data used for determining each of the components of the compensation of our CEO, each of our other NEOs, and other members of our executive management team, as well as for our non-employee directors;
- Advice on industry compensation practices, including the structure and mix of equity compensation; and
- Participation in several of our Compensation Committee's meetings in fiscal 2022.

In addition, the members of the Radford team provided advice to our Compensation Committee. Other than providing data as mentioned below, the Radford team did not provide any other services to Enanta. Management works with Radford at the direction of the Committee to provide the consultant with all information it deems necessary to advise the Committee. Radford follows internal guidelines and practices to guard against any conflict of interest and to ensure the objectivity of its advice and has confirmed the same in writing to our Compensation Committee. After review and consultation with Radford, our Compensation Committee has determined that Radford is independent of the company and the members of the Committee.

In September 2022, our Compensation Committee engaged Alpine Rewards LLC, or Alpine, to provide compensation consultant services for fiscal 2023. Alpine also advised our Compensation Committee on the composition of our peer group for purposes of year-end calendar 2022 compensation analysis and determinations.

Role of Company Management

Our CEO makes recommendations to our Compensation Committee concerning our company performance relative to corporate performance objectives and proposed compensation of the other NEOs and any other executive officers. In addition, our CEO leads management in setting the research and development objectives that are used as the performance objectives for the variable cash compensation plan, subject to Compensation Committee review and approval, and he reviews any adjustments to our proposed peer group and provides suggestions to Radford for inclusions or exclusions. Our CEO works closely with our Compensation Committee

to ensure that our Compensation Committee is provided with the appropriate information to make its decisions, including with respect to the performance of each of the other executive officers relative to each officer's individual annual performance objectives, and to propose recommendations for Compensation Committee consideration regarding the compensation elements for those NEOs. Once our CEO has made his recommendations to our Compensation Committee, this committee reviews them, including consultation with the other non-employee directors regarding our CEO's compensation, and makes the final compensation determinations. Once our Compensation Committee evaluates compensation data from Radford and makes its final determinations for the other NEOs and other executive officers, those determinations are delivered to our CEO, who then communicates them to the management team.

Benchmarking and Use of Peer Group Data

Our executive compensation program seeks to provide total compensation at pay levels of executives with similar roles at comparable companies when targeted levels of performance are achieved. Use of survey data from our peers plays a significant role in the structure of the compensation program because it is a primary input in setting target levels for base salaries, variable cash compensation and equity awards. These data also help to ensure that we provide compensation that is competitive with the market so that we can attract, retain and motivate talent.

As indicated above, our Compensation Committee retained Radford to conduct a study of peer companies for the purpose of reviewing the compensation levels of our executive team, including the NEOs. Radford provided proposed changes to our peer group to our Compensation Committee and our Compensation Committee then reviewed the peer group and, based on the available data and input from members of the Committee, determined and approved the final peer group. Our Compensation Committee used the peer group data to help identify a reasonable benchmark for base salaries, target variable cash compensation, time-based equity awards and target performance-based equity awards and then analyzed company and individual performance to determine whether it was appropriate to move away from this baseline. Peer group data also played a role in determining the non-cash compensation that was paid to the NEOs, as the market data we obtained regarding companies in our peer group informed what types and amounts of non-cash compensation are appropriate for competitive purposes.

The processes describe above regarding the roles of the compensation consultant and management and the use of benchmarking and peer group data in fiscal 2022 are consistent with our Compensation Committee's practices in prior years and with its continuing practices.

We believe that the design of our executive compensation program, with its emphasis on reward for achievement of the key objectives that comprise our annual and long-term business plan, does not create incentives for our executives to take excessive or unnecessary risks that could threaten the value of our company.

We also participate in compensation surveys conducted by Radford each year. The company has access to the resulting Radford reports, which are specific to the pharmaceutical and biotech industry and provide data on salaries, bonuses and equity grants for specific job functions. We use this information when reviewing the salaries and other compensation for all of our employees.

Our Compensation Committee retained Radford to conduct a competitive benchmarking analysis on executive compensation for compensation decisions that were made at this committee's November 2021 meeting. As an initial step in that process, Radford reviewed the prior year's criteria and, based on changes in our headcount and market capitalization, recommended changes for determining a peer group of companies that each met some or all of the following criteria, the first three of which were the primary criteria:

- Public biopharmaceutical companies with a product in Phase 2 or Phase 3 clinical development or on the market;
- Market capitalization generally between \$400 million and \$4 billion (preference for positive total stockholder returns);

- Annual revenue between \$75 million and \$675 million;
- Research and development expenditures between \$50 million and \$300 million; and
- Under 600 employees.

Radford reviewed the peer group approved by our Compensation Committee in calendar 2020 and determined that the profiles of these companies were within the calendar 2021 criteria, except for Assembly Biosciences and Esperion Therapeutics, which were removed from the peer group primarily due to their being outside of our market capitalization criteria. Dicerna Therapeutics and Xencor were then added to our peer group.

Based on the criteria set forth above, the final group of peer companies approved by our Compensation Committee in calendar 2021 was composed of the following companies:

Akebia Therapeutics	Arena Pharmaceuticals	Corcept Therapeutics
Dicerna Pharmaceuticals	FibroGen	Halozyme Therapeutics
Heron Therapeutics	ImmunoGen	Intercept Pharmaceuticals
Karyopharm Therapeutics	Ligand Pharmaceuticals	MacroGenics
Madrigal Therapeutics	Omeros	Poseida Therapeutics
PTC Therapeutics	Sangamo Therapeutics	Supernus Pharmaceuticals
Theravance Biopharma	Vanda Pharmaceuticals	Xencor

For purposes of year-end calendar 2022 compensation analysis and determinations, which occurred after the fiscal 2022. data presented in this proxy statement, our Compensation Committee, with the assistance of Alpine, made several changes to the peer group in October 2022. At that time, the criteria were adjusted to focus on companies with lead products in Phase 2 or Phase 3 clinical development or on the market (with a preference for companies in biotech “hub” locations and those focused on infectious diseases), annual revenues in the range of \$50 million to \$250 million and market capitalization generally between \$400 million and \$4 billion. Our Compensation Committee removed from the peer group Akebia, Halozyme, MacroGenics, Omeros and Poseida based on their market capitalizations, as well as Arena and Dicerna due to acquisition. Based on the revised criteria, our Compensation Committee added Agios Pharmaceuticals, Amicus Therapeutics, BioCryst Pharmaceuticals, Inmed, REGENXBIO, Traverre Therapeutics and Vir Biotechnology to our peer group for 2022.

Advisory “Say-on-Pay” Vote

At our 2022 Annual Meeting of Stockholders, approximately 95% of the shares voted on our annual “say-on-pay” proposal were cast in favor of the compensation of our named executive officers as disclosed in our 2022 proxy statement. The Compensation Committee considered the results of the 2022 shareholder advisory vote on executive compensation when determining the Company’s 2022 executive and NEO compensation and will continue to consider the results of shareholder advisory votes on executive compensation when making future decisions relating to our executive compensation programs and compensation for NEOs.

Executive Compensation Elements

The main components of our executive compensation program are:

- Base salary;
- Annual variable cash compensation;
- Long-term equity incentives awards consisting of:
 - stock options and restricted stock units with time-based vesting;
 - restricted stock units with two types of performance-based vesting; and
- Benefits, including 401(k) safe harbor match and medical benefits.

The following discussion describes how each of these elements of compensation fit into our overall compensation objectives and describes how and why compensation decisions were made by our Compensation Committee with respect to each element based on our compensation consultant’s analysis of competitive market data and our annual review of corporate and individual performance.

Base Salaries

Base salaries are paid in order to provide a fixed component of compensation for our NEOs and other executive officers to reward the individual value that each executive officer brings to us through experience and past and expected future contributions to our success. At our Compensation Committee meeting on November 17, 2021, the Committee established the base salaries of the NEOs for calendar year 2022 to be within a range that is competitive with salaries paid to executives in the 50th percentile among comparable executives at companies in our peer group. Our Compensation Committee increased the base salary of our CEO by approximately 4.8%, and each of other NEOs by approximately 3%, for calendar year 2022 from 2021 levels, primarily based on the applicable peer group data for comparable executives.

Annual Variable Cash Compensation

Our variable cash compensation program is intended to reward corporate performance and individual performance by providing our executive officers with an opportunity to receive additional cash compensation. Our CEO’s variable cash compensation is determined solely based on the company’s performance relative to the corporate objectives for the year. In the case of the other executive officers, variable cash compensation is based on both the company’s performance relative to the corporate objectives and our Compensation Committee’s assessment of how well the executive officer performed against his or her individual objectives during the applicable year, based substantially on the assessment of individual performance presented by our CEO. The target variable compensation is then subject to an overall limit of 150% of each NEO’s target amount.

Target Setting. Variable cash compensation targets, which are set as a percentage of base salary for all NEOs and other executive officers, were set within a range that is competitive with annual variable cash compensation paid to executives in the 50th percentile among comparable executives at companies in our peer group. Our Compensation Committee has the discretion to adjust each NEO’s target as it deems appropriate. Potential reasons for adjusting targets for variable cash compensation include considerations of pay equity within Enanta and how the officer’s base salary, upon which the variable cash compensation is based, has increased historically.

Elements of Variable Cash Compensation. For all executive officers other than the CEO, target variable cash compensation is determined based on two components: corporate performance and individual performance with 70% of variable cash compensation based on corporate performance and 30% on individual performance. The target percentages and the relative weighting of objectives for the NEOs for the variable cash compensation paid at the end of calendar 2022 were as follows:

	Target % for Variable Cash	Relative Weighting	
		Corporate	Individual
Jay R. Luly, Ph.D.	70%	100%	0%
Scott T. Rottinghaus, M.D.	45% ⁽¹⁾	70%	30%
Yat Sun Or, Ph.D.	40%	70%	30%
Nathaniel S. Gardiner, J.D.	40%	70%	30%
Paul J. Mellett	40%	70%	30%

(1) Dr. Rottinghaus’ variable compensation was subject to the proration policy for all employees, including NEOs, who begin employment during the fiscal year.

Corporate Performance Objectives. Near the beginning of each calendar year, our Compensation Committee, after considering the recommendations of management and our overall strategic goals, confirms our corporate objectives for the year and the proportional emphasis placed on each broad category of objectives. These objectives generally relate to categories that our Compensation Committee determines can add the most value to Enanta, such as research and development objectives, which constitute a substantial majority of the weighting of the objectives, and other factors primarily within management's control. Because the level of sales achieved for our products licensed to AbbVie are outside of management's control, those sales are not a factor considered in determining annual variable compensation. At the end of the year, our Compensation Committee determines the level of achievement of the corporate objectives for the year. This achievement level is then applied to the portion of each NEO's target variable compensation determined by corporate performance for that year.

Our annual corporate performance is determined based on achievement of one or more of the key research and development objectives for the year.

For calendar year 2021, our CEO proposed corporate objectives primarily focused on the advancement of our research programs, our clinical programs and external opportunities to augment our research and development pipeline, using a relative weighting for each category of objectives with a maximum payout of 150% for corporate performance. Our Compensation Committee then reviewed and approved these 2021 objectives in December 2020. In November 2021 our Compensation Committee reviewed our performance against these objectives and, in the context of the COVID-19 pandemic, determined a corporate performance rating based on objectives related to the following:

- Nomination of EDP-235 as our first 3CL protease candidate for treatment of SARS-CoV-2 infection and filing of an IND for its clinical development;
- Investigational New Drug Application filing for HBV RNA destabilizer EDP-721 and initiation of a Phase 1 study;
- Nomination of EDP-323 as our first RSV L-inhibitor candidate;
- Completion of two Phase 1b studies of EDP-514 (NUC-suppressed patients and viremic patients) and publication of data;
- Delivery of first interim analysis in the ARGON-2 Phase 2b study of EDP-305; and
- Delivery of topline data from the Phase 1 study of EDP-297.

Our Compensation Committee, which has full discretion to determine corporate performance against our annual corporate objectives, determined that we had achieved, or would achieve, sufficient results against the calendar 2021 performance objectives to award a corporate performance rating of 120%. After reviewing our CEO's recommendations with respect to the individual performance of the NEOs other than our CEO, our Compensation Committee also determined that our Chief Scientific Officer achieved an individual performance rating of 120% for his individual objectives, several of which were specific research and clinical development objectives closely tied to the company's ability to achieve the corporate objectives described above, and that our Chief Financial Officer and our Senior Vice President and General Counsel, achieved individual performance ratings of 95% and 105% respectively, for their individual objectives related to the performance of their respective groups and their individual responsibilities.

For calendar year 2022, our CEO proposed corporate objectives primarily focused on the advancement of our research programs, our clinical programs and external opportunities to augment our research and development pipeline, using a relative weighting for each category of objectives with a maximum payout of 150% for corporate performance. Our Compensation Committee then reviewed and approved these 2022 objectives in December 2021. In November 2022 our Compensation Committee reviewed our performance against these objectives and determined a corporate performance rating based on objectives related to the following:

- Completion of the Phase 1 study, and initiation and advancement of the Phase 2 study, of EDP-235 for treatment of SARS-CoV-2 infection;

- Topline data from the RSVP Phase 2 study of EDP-938 in otherwise healthy adults with RSV infection;
- Investigational New Drug Application filing and initiation and advancement of the Phase 1 study of RSV L-inhibitor EDP-323;
- Initiation of the Phase 2b study of EDP-938 in high-risk adults with RSV infection;
- Advancement of lead back-up 3CL protease inhibitor for treatment of SARS-CoV-2 infection;

Our Compensation Committee also took into account the successful advancement of our SARS-CoV-2 patent prosecution strategy, issuance of U.S. Patent No. 11,358,953 and initiation of the patent infringement lawsuit related to the nirmatrelvir component of Paxlovid, which was not a corporate objective at the beginning of the year.

Our Compensation Committee, which has full discretion to determine corporate performance against our annual corporate objectives, determined that we had achieved, or would achieve, sufficient results against the calendar 2022 performance objectives to award a corporate performance rating of 90%. After reviewing our CEO's recommendations with respect to the individual performance of the NEOs other than our CEO, our Compensation Committee also determined that our other NEOs all achieved an individual performance rating of 100% for their individual objectives related to the performance of their respective groups and their individual responsibilities.

Given that we have a September 30 fiscal year-end, the "Summary Compensation Table" following this discussion includes information, under the column "Non-Equity Incentive Plan Compensation", that is a prorated blend of the actual variable cash compensation earned by each NEO in calendar 2022 and 2021 (i.e., the proration in fiscal year 2022 was 25% of variable cash compensation for performance in the calendar year ending December 31, 2021 and 75% of variable cash compensation for the calendar year ending December 31, 2022).

Long-term Equity Incentive Awards

Equity awards have the potential to be a significant component of each NEO's compensation package. We emphasize equity awards to motivate our NEOs to drive the long-term performance of Enanta and to align their interests with those of our stockholders. We believe this emphasis is appropriate as these officers have the greatest role in establishing Enanta's direction and should have a significant proportion of their compensation aligned with the long-term interests of stockholders. Our Compensation Committee has established two types of equity awards, each of which now has two components, to serve these long-term incentives.

Equity Awards with Time-Based Vesting. Our Compensation Committee has traditionally made annual awards of stock options to provide a certain amount of equity to officers that will vest as long as the officer continues to work at Enanta. These grants align the interests of our NEOs with those of our stockholders because the grants will only have value if the market value of our common stock increases from the date of grant. To encourage retention and focus our executives on building long-term value for our stockholders, we structure our annual stock option awards so that they vest over a service period of four years. The size of stock option awards for our NEOs is then set within a range that is competitive with the Black-Scholes value of equity awards granted to comparable officers at companies in our peer group. The number of shares subject to each NEO stock option is based primarily on Radford's determination of the Black-Scholes value of equity awards granted to executives in the 50th percentile of executives in comparable roles in our peer group companies, and then using that value to determine a number of shares of our common stock based on our Black-Scholes formula used to value our stock options in our financial statements. Beginning in November 2020, based primarily on a determination to provide a portion of annual awards as full value awards that would not lose substantially all perceived value in a downturn of the price of our common stock, our Compensation Committee decided to replace a portion of the target value of what would otherwise have been stock option awards with an award of restricted stock units, or RSUs, that vest annually over four years. The number of full-value RSU awards is based on the Black-Scholes

value of the target number of stock options that the RSUs are replacing, using the same formula inputs as are used to value our stock options in our financial statements. Our Compensation Committee makes final adjustments to the specific number of shares after receiving recommendations from our CEO. The percentages of the annual equity awards that are allocated to options and to RSUs are made each year by our Compensation Committee, and in fiscal 2020 and 2021 the committee made the determination to allocate one third of the Black-Scholes value of the annual equity awards to RSU awards.

On November 17, 2021, our Compensation Committee granted to each of our NEOs (i) non-statutory stock options vesting over four years in equal quarterly installments with respect to a designated number of shares as follows: Dr. Luly, 107,800 shares, and each of Dr. Or and Messrs. Mellett and Gardiner, 28,400 shares; and (ii) RSUs vesting over four years in equal annual installments with respect to a designated number of shares as follows: Dr. Luly, 25,700 shares, and each of Dr. Or and Messrs. Mellett and Gardiner, 6,800 shares.

Dr. Rottinghaus was not eligible for annual equity awards with time-based vesting in November 2021 because he joined the company in August 2022, when he received a new-hire non-statutory stock option award for 75,000 shares and an RSU award of 20,000 shares. As with all new-hire awards, his stock option award vests as to 25% of the shares after one year and as to the balance of the shares in equal quarterly installments over the following three years, and his RSUs vest in four equal annual installments over four years. The number of shares in his awards were based primarily on Radford's determination of the Black-Scholes value of new-hire equity awards granted to executives in the 50th percentile of executives in comparable roles in our peer group companies, which value was then used to calculate a number of shares of our common stock for a stock option and for an RSU using the same formula described above for the annual awards.

Restricted Stock Units with Performance-Based Vesting. To provide additional incentive for longer-term performance that can allow our executive officers to achieve levels of equity awards, when aggregated with their time-based equity awards, our Compensation Committee also makes annual awards of performance share units, or PSUs, and relative total stockholder return units, or rTSRUs, to each of our executive officers. Half of these units are designed to vest based on high levels of performance against specific research and development and non-financial business objectives of Enanta over a two-year period. The other half are designed to vest if there is a high relative total stockholder return on our common stock versus the stocks of the other companies in the Nasdaq Biotechnology Index when comparing a two-month period at baseline to the comparable period two years later.

Our Compensation Committee has determined that a 2-year performance period is appropriate because, unlike more mature companies that have performance units vesting based on improving financial performance with numerically precise criteria, value in Enanta (whether directly measured by our stock price or events that affect that price) is created based on non-financial advances in our research and development programs, none of which has advanced yet beyond phase 2. In addition, the performance criteria for PSUs need to be precisely and rigorously defined even though they are subject to non-financial metrics. General experience in research and development in biotechnology has demonstrated that over a period of two years these types of early-stage programs rarely progress exactly as planned, primarily due to matters outside of management's control, such as failures in preclinical testing or unexpected side-effects or lack of efficacy in early-stage human studies. As a result, trying to set objective targets more than two years ahead would likely fail to provide any effective incentive during the full performance period since the chances would significantly increase that the objective would become unattainable well before the end of the performance period.

The target number of these performance units in fiscal 2022 was determined as follows:

- To initially bracket the number of units, Radford determined the difference in the dollar values of the annual equity awards for executives in the 50th percentile and the 75th percentile of comparable executives in our peer group companies;
- Radford then converted that differential value into a preliminary number of full value shares of our common stock based on our Black-Scholes formula used to value our stock options in our financial statements;

- Our Compensation Committee then adjusted those numbers of shares to determine a target number of total units for each NEO, based in part on considerations of pay equity and the relative roles of the NEOs; and
- The resulting target number of units was then split evenly between PSUs and rTSRUs for each NEO.

These unit awards have a performance period of two years, ending on December 31 of the second year. Our Compensation Committee determines the level of performance achieved, but the Committee does not retain discretion to adjust any of the performance criteria. For example, the Committee did not make any adjustment to the performance milestones for the PSUs with performance periods ending in 2020 or 2021, despite the delays and other material impacts of the COVID-19 pandemic that affected our ability to achieve several of the research and development milestones. Once the level of performance is determined, and provided that the NEO is still employed at Enanta, the underlying shares that have vested then settle and are issued to the NEO in the February following the end of the second year.

In the case of the PSUs awarded in fiscal 2022, unit vesting will be based on achievement of research and development milestones in each of three categories of activities: (i) advancement of clinical programs; (ii) advancement of research programs; and (iii) other value-driving opportunities generally involving assets outside of our research and development programs. These milestones, which relate to our key programs, are weighted based on our Compensation Committee's assessment of the relative value of the milestones. Each milestone is considered to be challenging to achieve, meaning that the likelihood of success during the performance period is possible, but not high. This also means that the chances that multiple milestones are achieved is even lower than for any single milestone. In the case of program milestones, every development activity for the particular program will have to progress substantially as planned in order to achieve the two-year objective for that program. Early-stage programs often experience delays. In addition, the failure rate is quite high for compounds in the early stages of discovery and preclinical and early clinical development. In the case of milestones for assets outside of Enanta, achievement will require success in identifying an available asset, validating the potential of the asset and its value to Enanta, and negotiating and completing a transaction on terms acceptable to all parties, much of which is outside of Enanta's control. For these reasons we call the PSU milestones "stretch goals" because they are hard to reach, i.e., achieve, as has been the case in each of the past three years. In fiscal years 2022, 2021 and 2020 we achieved PSU milestones that earned our executives 15%, 0%, and 15% respectively, of their target number of PSU shares that were eligible for vesting during those years.

On December 21, 2021, our Compensation Committee awarded our executive officers PSUs with milestones in each of three categories:

- Clinical milestones: Specific clinical milestones for each of EDP-235 (COVID-19), EDP-938 (RSV), EDP-514 (HBV), and EDP-323 (RSV), as well as the possibility of in-licensing and advancement of an external compound.
- Research milestones: Specific research milestones for SARS-CoV-2 and hMPV and for additional HBV and liver disease compounds, as well as advancement of any new mechanism of action or compounds for a new disease area.
- Other value-driving milestones: Out-licensing of EDP-235 in 2022, in-licensing and advancement of a novel compound, identification and advancement of a combination therapy into a clinical study, or out-licensing of a clinical stage compound.

Achievement of one of the clinical milestones will vest 70% of each NEO's target number of PSU shares and achievement of a second clinical milestone will vest an additional 50% (reflecting a vesting of 120% of the target number of PSU shares), achievement of up to two research or two other value-driving milestones will each vest 15% of the target number of PSUs per milestone (reflecting a vesting of 30% of the target number of PSU shares in each of those categories), but achievement of more than two milestones in either of those two categories

or more than two clinical milestones will not vest any additional shares. In addition, 40% of the target number of PSU shares would vest upon achievement of the EDP-235 out-licensing milestone. If one milestone in each of the three categories is achieved by December 31, 2023 (other than EDP-235 out-licensing), then 100% of each NEO's target number of PSU shares will vest; if up to one additional research milestone is achieved, then an additional 15% of each NEO's target number of PSU shares will vest; if up to one additional other value-driving milestone is achieved then an additional 15% of each NEO's target number of PSU shares will vest, and an additional 40% would vest upon achievement of the EDP-235 out-licensing milestone, but in no event would more than 50% of the target number of shares vest upon achievement of any combination of the other value-driving milestones; and if, instead of any additional research or other value-driving milestones, an additional clinical milestone is achieved, then 150% of each NEO's target number of PSU shares will vest. The maximum payout for PSUs awarded in fiscal 2022 is capped at 150% of each NEO's target number of PSU shares.

In the case of the rTSRUs awarded on December 21, 2021, these awards will vest and result in the issuance of shares of our common stock based upon the relative ranking of the total stockholder return, or TSR, of Enanta's common stock in relation to the TSR of the component companies in the Nasdaq Biotechnology Index using a comparison of average closing stock prices over a measurement period using the 60-day period ended December 31, 2021 compared to the 60-day period ending December 31, 2023. The rTSRUs are intended to reward increases in the relative market value of our common stock that might not relate directly to specific long-term objectives of internal research and development efforts reflected in the PSUs but that nonetheless are reflected in our market value and our returns for our stockholders over the performance period. The number of market-based rTSRUs awarded represents the target number of shares of common stock that may be earned; provided, however, that the actual number of shares that may be earned ranges from 0% to 150% of the target number, depending on Enanta's ranking in that index. No rTSRU shares will vest if there is no increase in the value of Enanta's stock during the period, nor will any rTSRU shares vest if during the measurement period the percentage increase in the value of Enanta's stock is ranked below the 65th percentile when ranked with the TSRs of all the component companies in the Nasdaq Biotechnology Index. The rTSRUs will vest as to 50%, 100% or 150% of the target number of rTSRU shares if the stock is ranked at the 65th, the 75th or at or above the 85th percentiles, respectively. If our ranking falls between the 65th and 85th percentiles, there will be interpolation between the fixed vesting amounts of the 65th, 75th and 85th percentiles based on the relative ranking of our stock.

These PSU and rTSRU performance awards are designed to provide an opportunity to vest additional equity compensation in aggregate amounts equal to the difference between the Black-Scholes value of awards in the 50th percentile and those in the 75th percentile of our peer group companies. These awards vest only as to one half of the differential if Enanta achieves high levels of performance against the company's longer-term research and development objectives, and as to the other half if the percentage increase in Enanta's stock is at least in the top 35% relative to the returns (calculated as percentage increases) of the traded stocks of the other public biotechnology companies in the Nasdaq Biotechnology Index during the two-year period. The following table shows the percentage of the target numbers of PSU and rTSRUs shares that were paid out in each of the two-year performance periods ending in the three most recent calendar years, demonstrating a broad range of performance that is achievable with these performance awards.

	Percent of Target Number of Shares Earned		
	2019-2020	2020-2021	2021-2022
PSU shares earned	0%	15%	100%
rTSRU shares earned	0%	59%	127%
Total % of Target Shares earned	0%	37%	114%

Benefits

Health and Welfare Benefits. Our NEOs are eligible to participate in all of our employee benefit plans, including our medical, dental, vision, group life and disability insurance plans, in each case on the same basis as other employees. We believe that these health and welfare benefits help ensure that we have a productive and focused workforce through reliable and competitive health and other benefits.

Retirement Savings. All of our full-time employees, including our NEOs, are eligible to participate in our 401(k) plan. Pursuant to our 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit (which was \$19,500 in calendar 2020 and 2021 and \$20,500 in 2022), with additional salary deferrals not to exceed \$6,000 available to those employees 50 years of age or older, and to have the amount of this reduction contributed to our 401(k) plan. In addition, in fiscal 2021, 2020 and 2019 we made company contributions in the amount of 6% of base salary, up to a maximum of \$17,400, \$17,100 and \$16,800, respectively, per year. This was based on our policy of making profit-sharing contribution to each employee's account in amounts ranging from 3% to 6% of base salary and bonus compensation paid in the calendar year, regardless of whether the employee makes a contribution to the 401(k) plan in that year. The percentage of the profit-sharing contribution above 3% is based on Enanta's performance for the year. The 401(k) Plan currently does not offer the ability to invest in our securities.

Perquisites. We do not provide significant perquisites or personal benefits to our NEOs. We do, however, pay the premiums for term life insurance for NEOs.

Severance and Change of Control Benefits

Pursuant to employment agreements, our NEOs are entitled to specified benefits in the event of the termination of their employment under specified circumstances, including termination without cause or for good reason.

We believe that severance protections, particularly in the context of a change of control transaction, can play a valuable role in attracting and retaining executive officers, are an important part of an executive's total compensation package and are consistent with competitive practices. We believe that the occurrence, or potential occurrence, of a change of control will create uncertainty regarding the continued employment of our NEOs. This uncertainty results from the fact that many change of control transactions result in significant organizational changes, particularly at the senior executive level. Our practice, in the case of our employment agreements, has been to structure these change of control benefits as "double trigger" benefits. In other words, the change of control does not itself trigger benefits; rather, benefits are paid only if the employment of the NEO is terminated during the 12-month period after the change of control. We believe a "double trigger" benefit maximizes stockholder value because it prevents an unintended windfall to executives in the event of a friendly change of control, while still providing them appropriate protections as incentives to cooperate in negotiating any change of control in which their jobs may be at risk. Because we believe that a termination by the executive for good reason is conceptually the same as a termination by us without cause, and that in the context of a change of control potential acquirers would otherwise have an incentive to constructively terminate the executive's employment to avoid paying severance, we provide severance benefits in these circumstances. We have provided more detailed information about these benefits, along with estimates of their value under various circumstances, under the caption "*— Potential Payments Upon Termination, Including Termination After a Change in Control Transaction*" below.

Corporate Policies Covering Executive Compensation

Policy Against Hedging

As part of our securities trading policy, all employees, including executive officers, and members of our Board of Directors are prohibited from engaging in hedging transactions involving our securities, including short sales, including short sales "against the box," and purchases or sales of puts, calls or other derivative securities.

Policy Against Pledging

Our insider trading policy also prohibits pledges of our securities by all employees, including executive officers, and members of our Board of Directors, including purchases of our securities on margin, borrowing against our securities held in a margin account or pledging our securities as collateral for a loan.

Policy Against Repricing Stock Options

We have a consistent policy against the repricing of stock options without stockholder approval.

Compensation Clawback Policy

Our Board of Directors has adopted a Compensation Clawback Policy that is applicable to our executive officers, and such other of our senior executive team as may be determined by the Compensation Committee. If we determine that we must restate our financial results as reported in a periodic or other report filed with the SEC to correct an accounting error due to material noncompliance with any financial reporting requirement under the U.S. securities laws, we will be able to recover incentive compensation, both cash and equity-based, awarded or paid to an executive officer covered by the policy to the extent the officer's fraud or intentional misconduct was a material contributing factor to the need for the restatement and a lower award or payment would have been made to such officer based on the restated financial results. This policy will be reviewed in 2023 once a final rule under the Dodd Frank Act is promulgated by Nasdaq.

Equity Incentive Awards - Mechanics and Timing

Our Compensation Committee approves all equity awards to NEOs, including the CEO.

For annual option awards, the grant date is typically during the week in November when our Compensation Committee and the full Board of Directors meet. This schedule permits the annual awards to NEOs to be effective on the same date that all our employees receive their annual equity awards. Our Compensation Committee's procedure for timing of stock option awards assures that grant timing is not being manipulated for employee gain. This grant date timing coincides with Enanta's calendar-year-based employee review cycle, allowing managers to deliver the equity awards close in time to performance appraisals, which increases the impact of the awards by strengthening the link between pay and performance.

The exercise price for all stock options to the NEOs (including the CEO) is the fair market value of our common stock on the date of the grant. The fair market value of our common stock as of any particular date is defined by our Compensation Committee as the closing price of our common stock on that date.

Our Compensation Committee does not grant equity awards in anticipation of the release of material nonpublic information. Similarly, we do not time the release of material nonpublic information about the company based on equity award grant dates.

Federal Tax Considerations under Section 162(m)

Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, generally disallows a tax deduction to public companies for compensation in excess of \$1 million paid to each of a company's chief executive officer, chief financial officer and the three most highly compensated executive officers (other than the chief executive officer and chief financial officer), as well as any officer who was treated as a covered employee under Section 162(m) of the U.S. Internal Revenue Code of 1986, as amended, for any year beginning after December 31, 2016. All compensation in excess of \$1 million paid to each of the executives described above (other than certain grandfathered compensation in effect before November 2017) will not be deductible by us.

While our Compensation Committee considers the deductibility of awards as one factor in determining executive compensation, our Compensation Committee may also look at other factors in making its decisions and retains the flexibility to award compensation that it determines to be consistent with the goals of our executive compensation program even if the compensation is not deductible by us for tax purposes.

COMPENSATION COMMITTEE REPORT

This Compensation Committee has reviewed the Compensation Discussion and Analysis and discussed that analysis with management. Based on its review and its discussions with management, this Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.

By the Compensation Committee,

Kristine Peterson, Chair
Bruce L.A. Carter, Ph.D.
Yujiro S. Hata
Terry C. Vance

January 20, 2023

Summary Compensation Table

The following table sets forth information regarding compensation paid to our NEOs:

Name and Principal Position	Year	Salary (\$) ⁽¹⁾	Bonus (\$) ⁽²⁾	Stock Awards (\$) ⁽³⁾	Option Awards (\$) ⁽⁴⁾	Non-Equity Incentive Plan Compensation (\$) ⁽⁵⁾	All Other Compensation (\$) ⁽⁶⁾	Total (\$)
Jay R. Luly, Ph.D.	2022	725,050	—	2,305,881	3,739,269	483,032	19,424	7,272,656
<i>President and Chief</i>	2021	693,188	—	1,778,616	2,283,872	518,822	19,211	5,293,709
<i>Executive Officer</i>	2020	667,063	—	497,039	3,598,848	415,716	19,171	5,197,837
Scott T. Rottinghaus, M.D.*	2022	77,557	62,500	1,597,316	2,628,960	29,295	337	4,395,965
<i>Senior Vice President and</i>	2021	—	—	—	—	—	—	—
<i>Chief Medical Officer</i>	2020	—	—	—	—	—	—	—
Yat Sun Or, Ph.D.	2022	501,250	—	764,324	985,114	199,695	19,218	2,469,600
<i>Senior Vice President, Research &</i>	2021	486,525	—	609,830	652,535	224,010	19,211	1,992,111
<i>Development and Chief</i>	2020	472,075	—	187,821	981,504	184,230	19,171	1,844,801
<i>Scientific Officer</i>								
Nathaniel S. Gardiner, J.D.	2022	458,050	—	739,664	985,114	180,475	19,424	2,382,727
<i>Senior Vice President and</i>	2021	444,675	—	582,640	652,535	198,702	19,211	1,897,763
<i>General Counsel</i>	2020	431,025	—	187,821	981,504	169,470	19,171	1,788,991
Paul J. Mellett	2022	453,975	—	739,664	985,114	177,537	19,424	2,375,714
<i>Senior Vice President, Finance &</i>	2021	440,381	—	582,640	652,535	192,803	19,211	1,887,570
<i>Administration and Chief</i>	2020	425,894	—	187,821	981,504	167,453	19,171	1,781,843
<i>Financial Officer</i>								

* Dr. Rottinghaus joined the Company in August 2022.

- 1) The amounts shown in the “Salary” column represent the total base salary earned during the designated fiscal year. Annual cash compensation is determined by our Compensation Committee and is adjusted on a calendar year basis, effective at the beginning of the calendar year. The following were the base salaries approved by our Compensation Committee for each calendar year:

	Calendar Year		
	2022	2021	2020
Jay R. Luly, Ph.D.	\$733,400	\$700,000	\$672,750
Scott T. Rottinghaus, M.D.	\$525,000	\$ —	\$ —
Yat Sun Or, Ph.D.	\$505,000	\$490,000	\$476,100
Nathaniel S. Gardiner, J.D.	\$461,400	\$448,000	\$434,700
Paul J. Mellett	\$457,300	\$444,000	\$429,525

- 2) The amount shown in the “Bonus” column represents a sign-on bonus paid to the named executive officer.
- 3) The “Stock Awards” column includes unit awards made in the first quarter of the fiscal year, e.g., awards in November 2021 are shown in year 2022. In 2022 those awards reflect restricted stock unit awards granted in November 2021, as well as the performance unit awards granted in each year presented, including pro-rated performance unit awards granted to named executive officers hired during the fiscal year (as is the case with Dr. Rottinghaus) and a new hire restricted stock unit award granted to Dr. Rottinghaus when he commenced his employment in August 2022. The amounts in the “Stock Awards” column reflect the grant date fair value of the relative total stockholder return units, or rTSRUs, awarded during the respective fiscal year in accordance with Accounting Standards Codification (“ASC”) 718. The grant date fair value of the rTSRUs is determined based on a Monte Carlo simulation model as of the grant date. Monte Carlo assumptions used in this calculation are included beginning on page F-20 in Footnote 10 of our Annual Report on Form 10-K for the year ended September 30, 2022, referred to herein as our 2022 Form 10-K. In each case, the rTSRUs that are granted annually measure relative stockholder return during a period at the end of the calendar year

in which the number of rTSRUs is determined compared to the same calendar period two years later, regardless of when the grant date of the rTSRUs occurs.

A total of 59% of the rTSRUs granted in December 2019 (represented in row 2020) vested at December 31, 2021, because our total stockholder return relative to such companies was between the 65th and 75th percentiles. A total of 127% of the rTSRUs granted in December 2020 (represented in row 2021) vested at December 31, 2022, because our total stockholder return relative to such companies was between the 75th and 85th percentiles. The rTSRUs granted in December 2021 (represented in column 2022) will not be eligible for vesting until December 31, 2023.

The values of the maximum payouts possible for the 2022, 2021, and 2020 rTSRU awards based on the fair value of the rTSRUs at the respective dates of grant and the maximum number of shares issuable under the unit awards based on performance of our common stock are as follows:

	Fiscal Year Ended September 30,		
	2022	2021	2020
Jay R. Luly, Ph.D.	\$554,850	\$936,016	\$745,558
Scott T. Rottinghaus, M.D.	\$257,874	\$ —	\$ —
Yat Sun Or, Ph.D.	\$378,120	\$418,046	\$281,732
Nathaniel S. Gardiner, J.D.	\$341,130	\$377,261	\$281,732
Paul J. Mellett	\$341,130	\$377,261	\$281,732

The amounts in the “Stock Awards” column for fiscal years 2022, 2021, and 2020 reflect the grant date fair values of the rTSRUs granted to our NEOs in December 2021 and August 2022 (for fiscal year 2022), December 2020 (for fiscal year 2021), and December 2019 (for fiscal year 2020), respectively, when the awards were made, and the same is true for the amounts shown in the tables in this note for the grant date fair values of the PSUs and the rTSRUs.

The amounts in the “Stock Awards” column for fiscal year 2022 also include the grant date fair values of restricted stock units granted to our NEOs in December 2021 and August 2022 (for fiscal year 2022). The fair values of the restricted stock units are based on the closing price of our common stock on the respective dates of grant in accordance with Accounting Standards Codification (“ASC”) 718.

The “Stock Awards” column does not include the grant date fair value of the performance share units, or PSUs, awarded during each fiscal year presented because it was not probable at the respective date of grant that the awards would ultimately vest. The PSUs only vest on achievement of specific performance targets that must be achieved over a two-year period ending on December 31 of the second year. A portion of the grant date fair value of a PSU is only recorded in our financial statements, if ever, when it is probable that the corresponding research or development milestone will be achieved. The grant date fair values of the target number of PSUs awarded in 2022, 2021, and 2020, which values were based on the fair market value of the stock on the date of grant using the closing price of our common stock on that date, were as follows:

	Fiscal Year Ended September 30,		
	2022	2021	2020
Jay R. Luly, Ph.D.	\$522,383	\$1,011,407	\$693,749
Scott T. Rottinghaus, M.D.	\$229,489	\$ —	\$ —
Yat Sun Or, Ph.D.	\$355,994	\$ 451,717	\$262,154
Nathaniel S. Gardiner, J.D.	\$321,169	\$ 407,647	\$262,154
Paul J. Mellett	\$321,169	\$ 407,647	\$262,154

A total of 15% of the target amounts of PSUs granted in December 2019 (fiscal 2020) vested at December 31, 2021. A total of 100% of the PSUs granted in December 2020 (fiscal 2021) vested at December 31, 2022. The PSUs granted in December 2021 and August 2022 (fiscal 2022) are not eligible for vesting until December 31, 2023.

The values of the maximum payouts possible for the 2022, 2021, and 2020 PSU awards, which are based on the fair market value of our common stock at the respective dates of grant, and the maximum number of shares issuable under these unit awards, were as follows:

	Fiscal Year Ended September 30,		
	2022	2021	2020
Jay R. Luly, Ph.D.	\$783,574	\$1,517,110	\$1,040,624
Scott T. Rottinghaus, M.D.	\$344,234	\$ —	\$ —
Yat Sun Or, Ph.D.	\$533,991	\$ 677,576	\$ 393,231
Nathaniel S. Gardiner, J.D.	\$481,753	\$ 611,471	\$ 393,231
Paul J. Mellett	\$481,753	\$ 611,471	\$ 393,231

- 4) The “Option Awards” column includes stock option awards made in the first quarter of the fiscal year, e.g., awards in November 2021 are shown in the year 2022. This also includes a new hire stock option award granted to Dr. Rottinghaus in fiscal 2022. The amounts in the “Option Awards” column reflect the grant date fair value of stock options awarded during the fiscal year computed in accordance with the provisions of ASC 718 using the Black-Scholes option-pricing model. Assumptions used in this calculation are included beginning on page F-18 in Footnote 10 of our 2022 Form 10-K.
- 5) The amounts shown in the “Non-Equity Incentive Plan Compensation” column represent a prorated blend of the annual variable cash compensation earned in the calendar years covering the corresponding fiscal year based on corporate and individual performance during the calendar year (e.g., the prorated blend in fiscal year 2022 was 25% of variable cash compensation for performance in the calendar year 2021 and 75% of variable cash compensation for the calendar year 2022). Variable cash compensation is based on corporate and individual performance against objectives proposed by management and approved by our Compensation Committee, which makes the final determination regarding the level of achievement against these objectives. The following presents the target variable compensation percentages applicable to each executive officer for the calendar year bonus paid in the corresponding fiscal year:

	Calendar Year Target Variable Compensation		
	2022	2021	2020
Jay R. Luly, Ph.D.	70%	65%	65%
Scott T. Rottinghaus, M.D.	45%	*	*
Yat Sun Or, Ph.D.	40%	40%	40%
Nathaniel S. Gardiner, J.D.	40%	40%	40%
Paul J. Mellett	40%	40%	40%

- * Dr. Rottinghaus did not have a target variable cash compensation for 2021 and 2020 because he was hired during 2022. His variable compensation in 2022 was subject to the proration policy for all employees, including NEOs, who begin employment during a fiscal year.
- 6) Includes employer matching contributions for Dr. Luly, Dr. Or, Mr. Gardiner and Mr. Mellett under our 401(k) plan in the amounts of \$17,400, \$17,100 and \$16,800 in fiscal 2022, 2021, and 2020, respectively. Dr. Rottinghaus, who was hired in the last quarter of fiscal 2022, received no employer matching contributions under our 401(k) plan during any of those fiscal years. The table also includes company-paid premiums for Dr. Luly, Mr. Gardiner and Mr. Mellett for group term life insurance, short term disability and accidental death and dismemberment insurance and reimbursement for the cost of long-term disability insurance in the aggregate amounts of \$2,024, \$2,111, and \$2,371 for fiscal 2022, 2021 and 2020, respectively. For Dr. Or the cost was \$1,818, \$2,111 and \$2,371. For Dr. Rottinghaus, who was hired during fiscal 2022, the table includes company-paid premiums for group term life insurance, short term disability and accidental death and dismemberment insurance and reimbursement for the cost of long-term disability insurance in the aggregate amount of \$337 for fiscal 2022.

2022 Grants of Plan-Based Awards

The following table sets forth certain additional information regarding grants of plan-based awards to our NEOs for our 2022 fiscal year under our 2019 Equity Incentive Plan:

	Estimate possible payouts under non-equity incentive plan awards ⁽¹⁾		Grant Date	Estimated future payouts under equity incentive plan awards ⁽²⁾			All other stock awards ⁽³⁾ :	All other option awards ⁽⁴⁾ :	Exercise or base price of option awards (\$)	Grant date fair value of stock and option awards (\$)
				Target (\$)	Maximum (\$)	Threshold (#)	Target (#)	Maximum (#)		
Jay R. Luly, Ph.D.	\$498,785	\$748,178								
2022 Options			11/19/2021	—	—	—	—	107,800	\$75.33	\$3,739,269
2022 RSUs			11/19/2021	—	—	—	27,500	—	—	\$1,935,981
2022 rTSRUs			12/21/2021	3,375	6,750	10,125	—	—	—	\$ 369,900
2022 PSUs			12/21/2021	1,012	6,750	10,125	—	—	—	\$ —
Scott T. Rottinghaus, M.D.	\$ 94,500	\$141,750								
2022 Options			8/8/2022	—	—	—	—	75,000	\$71.27	\$2,628,960
2022 RSUs			8/8/2022	—	—	—	20,000	—	—	\$1,425,400
2022 rTSRUs			8/8/2022	1,610	3,220	4,830	—	—	—	\$ 171,916
2022 PSUs			8/8/2022	483	3,220	4,830	—	—	—	\$ —
Yat Sun Or, Ph.D.	\$200,500	\$300,750								
2022 Options			11/19/2021	—	—	—	—	28,400	\$75.33	\$ 985,114
2022 RSUs			11/19/2021	—	—	—	6,800	—	—	\$ 512,244
2022 rTSRUs			12/21/2021	2,300	4,600	6,900	—	—	—	\$ 252,080
2022 PSUs			12/21/2021	690	4,600	6,900	—	—	—	\$ —
Nathaniel S. Gardiner, J.D.	\$183,220	\$274,830								
2022 Options			11/19/2021	—	—	—	—	28,400	\$75.33	\$ 985,114
2022 RSUs			11/19/2021	—	—	—	6,800	—	—	\$ 512,244
2022 rTSRUs			12/21/2021	2,075	4,150	6,225	—	—	—	\$ 227,420
2022 PSUs			12/21/2021	623	4,150	6,225	—	—	—	\$ —
Paul J. Mellett	\$181,590	\$272,385								
2022 Options			11/19/2021	—	—	—	—	28,400	\$75.33	\$ 985,114
2022 RSUs			11/19/2021	—	—	—	6,800	—	—	\$ 512,244
2022 rTSRUs			12/21/2021	2,075	4,150	6,225	—	—	—	\$ 227,420
2022 PSUs			12/21/2021	623	4,150	6,225	—	—	—	\$ —

- 1) The amounts in these columns represent target and maximum payouts based on a prorated blend of 25% of variable cash compensation for individual and corporate performance in the calendar year 2021 and 75% of variable cash compensation for the calendar year 2022. There is no threshold-level payout for such variable cash compensation. The maximum payout is 150% of the target payout. The actual amount earned by each NEO is reported under the “Non-Equity Incentive Plan Compensation” column in the Summary Compensation Table. For additional information about our annual variable cash compensation and a discussion of how these amounts are determined, please see “Compensation Discussion and Analysis – Annual Variable Cash Compensation” in this proxy statement.

- 2) There are two types of equity awards included in these columns:

Performance Unit Awards (“PSUs”)

The fair values of the PSUs granted in fiscal 2022 were not included in the table above because on the date of grant it was not probable that any of the underlying performance milestones would be achieved. The PSUs granted to Drs. Luly, Or and Rottinghaus and Messrs. Gardiner and Mellett in fiscal 2022 will vest as to percentages of the target number of unit shares only upon achievement of specified milestones within three research and development categories by the end of calendar year 2023, with the actual number of unit shares that may be earned ranging from 0% to 150% of the target number. Included in the table above are prorated PSUs (“2022 PSUs”) awarded during fiscal 2022 in conjunction with the start of employment of Dr. Rottinghaus, which awards, like those for our other NEOs, will vest if there is achievement by the end of calendar 2023 of specified milestones within three research and development categories identified by the compensation committee in December 2021. Additional details regarding the specified milestones are set forth earlier in this proxy statement under “EXECUTIVE COMPENSATION – Compensation Discussion and Analysis – Long-Term Equity Incentive Awards – Restricted Stock Units with Performance-Based Vesting.”

The values of the threshold, target and maximum payouts possible for the fiscal 2022 PSU awards are based on the fair value at the date of grant and the threshold, target and maximum number of units issuable are as follows:

	<u>Threshold</u>	<u>Target</u>	<u>Maximum</u>
Jay R. Luly, Ph.D.	\$78,357	\$522,383	\$783,574
Scott T. Rottinghaus, M.D.	\$34,423	\$229,489	\$344,234
Yat Sun Or, Ph.D.	\$53,399	\$355,994	\$533,991
Nathaniel S. Gardiner, J.D.	\$48,175	\$321,169	\$481,753
Paul J. Mellett	\$48,175	\$321,169	\$481,753

If none of the specified goals within the three research and development categories is achieved by the end of the 2023 calendar year, none of the unit shares will vest.

Relative Total Stockholder Return Units (“rTSRUs”)

The rTSRUs granted in fiscal 2022 (the “2022 rTSRUs”) will vest as to percentages of the target number of unit shares based on the relative ranking of the total stockholder return of our common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotechnology Index over a two-year period based on a comparison of average closing stock prices in the last 60 trading days of calendar 2021 and calendar 2023. The actual number of shares that may be earned under the market-based unit ranges from 0% to 150% of the target number.

Included in the table above are prorated rTSRUs that Dr. Rottinghaus received in conjunction with the start of his employment during fiscal 2022, which otherwise have the same terms similar as the TSRU awards granted to other executive officers for the performance period ending December 31, 2023.

The values of the threshold, target and maximum payouts possible for the 2022 rTSRU awards based on the fair value at the date of grant and the threshold, target and maximum number of units issuable, based on the performance of our common stock, are set forth below. These values differ from those for the PSU awards because they are valued based on a Monte Carlo simulation model, as noted in Note 2 to the Summary Compensation Table above.

	<u>Threshold</u>	<u>Target</u>	<u>Maximum</u>
Jay R. Luly, Ph.D.	\$184,950	\$369,900	\$554,850
Scott T. Rottinghaus, M.D.	\$ 85,958	\$171,916	\$257,874
Yat Sun Or, Ph.D.	\$126,040	\$252,080	\$378,120
Nathaniel S. Gardiner, J.D.	\$113,710	\$227,420	\$341,130
Paul J. Mellett	\$113,710	\$227,420	\$341,130

For the 2022 rTSRU awards, the minimum relative total stockholder return, or threshold, to achieve a threshold payout of 50% of the target number of shares requires a percentage increase in the value of Enanta’s stock that causes it to be ranked in at least the 65th percentile among the TSRs of all the component companies in the Nasdaq Biotechnology Index. If the threshold, as approved by our Compensation Committee, is not achieved during the measurement period ending at the end of calendar 2023, or if there is no increase in the value of Enanta stock during the measurement period, none of the unit shares will vest.

3) Restricted Stock Unit Awards (“RSUs”)

In November 2021, the Company awarded restricted stock units to Drs. Luly and Or and Messrs. Gardiner and Mellett, which vest in equal annual installments on December 1st over four years, provided the NEO remains employed with the Company at the time of vesting. In addition, as part of his hiring, Dr. Rottinghaus was awarded restricted stock units which vest in equal annual installments on August 8th over four years, provided he remains employed with the Company at the time of vesting. The fair value of these awards was determined based on the fair value of the stock on the date of grant. The aggregate grant date fair value of restricted stock units granted during the fiscal year is computed in accordance with the provisions of ASC 718.

4) Stock Options

Each of the option awards has a ten-year term and they vest over four years. The aggregate grant date fair value of stock options granted during the fiscal year is computed in accordance with the provisions of ASC 718. The exercise price of the options is equal to the closing price of our common stock on the date of grant.

2022 Options Exercised and Stock Awards Vested

The following table sets forth the value realized by our NEOs from options to purchase common stock exercised by the NEOs during fiscal 2022 and shares of common stock underlying unit awards that settled during fiscal 2022. The value realized per share for options is based on the difference between the exercise price and the fair market value of our common stock on the date the options were exercised. The value realized upon vesting of the stock awards is based on the fair market value of the shares on the settlement date of the unit awards.

	<u>Option Awards</u>		<u>Stock Awards (1)</u>	
	<u>Number of Shares Acquired on Exercise (#)</u>	<u>Value Realized on Exercise (\$)</u>	<u>Number of Shares Acquired on Vesting (#)</u>	<u>Value Realized on Vesting (\$)</u>
Jay R. Luly, Ph.D.	10,063	\$460,721	14,653	\$1,082,549
Scott T. Rottinghaus, M.D.	—	—	—	—
Yat Sun Or, Ph.D.	—	—	4,934	\$ 356,186
Nathaniel S. Gardiner, J.D.	—	—	4,934	\$ 356,186
Paul J. Mellett	3,480	\$100,863	4,934	\$ 356,186

(1) These stock awards consist of 25% of the service-based RSUs granted in November 2020 that vested and settled in December 2021, as well as 15% and 59% of the target numbers of PSUs and rTSRUs, respectively, granted in December 2019 that vested and then settled in February 2022.

Outstanding Equity Awards at Fiscal 2022 Year-End

The following table summarizes the outstanding equity award holdings of our NEOs as of September 30, 2022:

Named Executive Officers	Grant Date	Option Awards				Stock Awards			
		Number of Securities Underlying Unexercised Options (# Exercisable)	Number of Securities Underlying Unexercised Options (# Un-exercisable)	Option Exercise Price (\$/Sh)	Option Expiration Date	Number of shares or units of stock that have not vested (#) ¹	Market value of shares of stock that have not vested (\$) ²	Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) ³	Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested (\$) ⁴
Jay R. Luly, Ph.D.	12/26/2012	16,149	—	\$14.18	12/26/2022				
	3/21/2013	41,763	—	\$14.00	3/21/2023				
	12/5/2013	70,000	—	\$27.58	12/5/2023				
	12/9/2013	25,000	—	\$29.66	12/9/2023				
	11/20/2014	85,250	—	\$44.00	11/20/2024				
	11/20/2015	110,000	—	\$31.42	11/20/2025				
	11/18/2016	120,000	—	\$30.00	11/18/2026				
	11/17/2017	100,000	—	\$48.52	11/17/2027				
	11/16/2018	63,750	4,250	\$81.20	11/16/2028				
	11/18/2019	75,625	34,375	\$63.35	11/18/2029				
	11/20/2020	47,162	60,638	\$43.57	11/20/2030				
	11/19/2021	20,212	87,588	\$75.33	11/19/2031				
	11/20/2020					19,875	\$ 1,030,916		
	12/18/2020							22,950(a)	\$1,190,417
	12/18/2020							22,950(b)	\$1,190,417
	11/19/2021					25,700	\$ 1,333,059		
12/21/2021							6,750(c)	\$ 350,123	
12/21/2021							6,750(d)	\$ 350,123	
Scott T. Rottinghaus, M.D.	8/8/2022	—	75,000	\$71.27	8/8/2032				
	8/8/2022					20,000	\$ 1,037,400		
	8/8/2022							3,220(c)	\$ 167,021
	8/8/2022							3,220(d)	\$ 167,021
Yat Sun Or, Ph.D.	3/21/2013	13,925	—	\$14.00			3/21/2023		
	12/5/2013	35,000	—	\$27.58			12/5/2023		
	12/9/2013	12,500	—	\$29.66			12/9/2023		
	11/20/2014	36,500	—	\$44.00			11/20/2024		
	11/20/2015	33,000	—	\$31.42			11/20/2025		
	11/18/2016	35,000	—	\$30.00			11/18/2026		
	11/17/2017	23,500	1,250	\$48.52			11/17/2027		
	11/16/2018	18,750	9,375	\$81.20			11/16/2028		
	11/18/2019	20,625	17,325	\$63.35			11/18/2029		
	11/20/2020	13,475	17,325	\$43.57			11/20/2030		
	11/19/2021	5,325	23,075	\$75.33			11/19/2031		
	11/20/2020					5,700	\$ 295,659		
12/18/2020							10,250(a)	\$ 531,668	

Named Executive Officers	Option Awards					Stock Awards			
	Grant Date	Number of Securities Underlying Unexercised Options (# Exercisable)	Number of Securities Underlying Un-exercised Options (# Un-exercisable)	Option Exercise Price (\$/Sh)	Option Expiration Date	Number of shares or units of stock that have not vested (#) ¹	Market value of shares of units of stock that have not vested (\$) ²	Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) ³	Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested (\$) ⁴
	12/18/2020							10,250(b)	\$ 531,668
	11/19/2021					6,800	\$352,716		
	12/21/2021							4,600(c)	\$ 238,602
	12/21/2021							4,600(d)	\$238,3602
Nathaniel S. Gardiner, J.D. . . .	5/9/2014	70,976	—	\$34.70	5/9/2024				
	11/20/2014	27,500	—	\$44.00	11/20/2024				
	11/20/2015	19,818	—	\$31.42	11/20/2025				
	11/18/2016	13,667	—	\$30.00	11/18/2026				
	11/17/2017	21,500	—	\$48.52	11/17/2027				
	11/16/2018	16,875	1,125	\$81.20	11/16/2028				
	11/18/2019	20,625	9,375	\$63.35	11/18/2029				
	11/20/2020	13,475	17,325	\$43.57	11/20/2030				
	11/19/2021	5,325	23,075	\$75.33	11/19/2031				
	11/20/2020					5,700	\$295,659		
	12/18/2020							9,250(a)	\$ 479,798
	12/18/2020							9,250(b)	\$ 479,798
	11/19/2021					6,800	\$352,716		
	12/21/2021							4,150(c)	\$ 215,261
	12/21/2021							4,150(d)	\$ 215,261
Paul J. Mellett ⁽⁵⁾	12/26/2012	4,148	—	\$14.18	12/26/2022				
	1/17/2013	2,812	—	\$14.18	1/17/2023				
	3/21/2013	10,440	—	\$14.00	3/21/2023				
	12/5/2013	17,500	—	\$27.58	12/5/2023				
	12/9/2013	6,250	—	\$29.66	12/9/2023				
	11/20/2014	16,250	—	\$44.00	11/20/2024				
	11/20/2015	14,999	—	\$31.42	11/20/2025				
	11/18/2016	14,999	—	\$30.00	11/18/2026				
	11/17/2017	11,250	—	\$48.52	11/17/2027				
	11/16/2018	8,906	594	\$81.20	11/16/2028				
	11/18/2019	20,625	9,375	\$63.35	11/18/2029				
	11/20/2020	13,475	17,325	\$43.57	11/20/2030				
	11/19/2021	5,325	23,075	\$75.33	11/19/2031				
	11/20/2020					5,700	\$295,659		
	12/18/2020							9,250(a)	\$ 479,798
	12/18/2020							9,250(b)	\$ 479,798
	11/19/2021					6,800	\$352,716		
	12/21/2021							4,150(c)	\$ 215,261
	12/21/2021							4,150(d)	\$ 215,261

(1) The awards in this column represent RSUs subject only to service-based vesting. The RSUs are to vest in four equal annual installments on the first four anniversaries of the awards.

- (2) The market values of these awards set forth in this table are based on the number of units (representing shares) shown multiplied by the closing price of our common stock on September 30, 2022 (\$51.87), as reported by the Nasdaq Global Select Market.
- (3) The awards included in this column represent PSUs and rTSRUs. This column shows the target number of shares that may be earned. The actual number of shares that may be earned ranges from 0% to 150% of the target number.
 - (a) These are PSUs that were to vest as to percentages of the target number of unit shares only upon Enanta's achievement of specified milestones within three categories on or before the end of the respective two- year performance period ending on December 31 of the second year, and then settle in February of the following year, subject to the NEO's continued employment with Enanta. Additional details regarding the specified milestones are set forth earlier in this proxy statement under "EXECUTIVE COMPENSATION – Compensation Discussion and Analysis – *Long-Term Equity Incentive Awards – Restricted Stock Units with Performance-Based Vesting.*" The actual number of unit shares that could be earned for achievement of one or more milestones ranged from 15% to 150% of the target number shown. As of December 31, 2022, a total of 100% of these PSUs vested based on the achievement of one clinical milestone and two of the non-clinical research milestones and will settle in February 2023, subject to the NEO's continued employment with Enanta.
 - (b) These rTSRUs were to vest based upon the relative ranking of the total stockholder return, or TSR, of Enanta's common stock in relation to the TSR of each of the component companies in the NASDAQ Biotechnology Index over a two-year period based on a comparison of average closing stock prices in the 60-day periods prior to December 31, 2020 and December 31, 2022. As of December 31, 2022, 127% of these rTSRUs had vested.
 - (c) These PSUs will vest as to percentages of the target number of unit shares only upon Enanta's achievement of specified milestones within three categories on or before December 31, 2023, and will settle in February 2024, subject to the NEO's continued employment with Enanta. The actual number of unit shares that may be earned range from 0% to 150% of the target number shown. The specified milestones for these PSUs are similar in scope to those referenced in note (a) above.
 - (d) These rTSRUs will vest based upon the relative ranking of the total stockholder return, or TSR, of Enanta's common stock in relation to the TSR of each of the component companies in the NASDAQ Biotechnology Index over a two-year period based on a comparison of average closing stock prices in the 60-day periods prior to December 31, 2021, and December 31, 2023, and will settle in February 2024, subject to the NEO's continued employment with Enanta.
- (4) The market values of the awards set forth in this column are based on the target number of units shown (representing shares) multiplied by the closing price of our common stock on September 30, 2022 (\$51.87), as reported by the Nasdaq Global Select Market.
- (5) Pursuant to a qualifying domestic relations order issued on November 19, 2019, one half of all Enanta securities held by Mr. Mellett on September 30, 2019 were transferred to his former spouse.

Potential Payments Upon Termination, Including Termination After a Change in Control Transaction

If Dr. Luly is terminated involuntarily without cause or constructively terminated, and such termination occurs within twelve months of a change in control transaction, these terms as defined in the executive employment agreements, he is entitled to the following: (i) a lump sum payment in an amount equal to the higher of (x) eighteen (18) months of his then current base salary or (y) eighteen (18) months of his base salary immediately prior to the effective date of the change in control, (ii) a lump sum payment equal to one hundred fifty percent (150%) of the target annual bonus for the period in which his employment is terminated and (iii) a continuation of benefit coverage for up to eighteen (18) months.

If any of Drs. Or or Rottinghaus or Messrs. Gardiner or Mellett is terminated involuntarily without cause or constructively terminated, and such termination occurs within twelve months of a change in control transaction, these terms as defined in the agreements, then each is entitled to following: (i) a lump sum payment in an amount equal to the higher of (x) twelve (12) months of his or her then current base salary or (y) twelve

(12) months of his base salary immediately prior to the effective date of the change in control, (ii) a lump sum payment equal to one hundred percent (100%) of the target annual bonus for the period in which his or her employment is terminated and (iii) a continuation of benefit coverage for up to twelve (12) months.

If Dr. Luly is terminated involuntarily without cause other than within twelve (12) months of a change in control transaction or if he voluntarily terminates his employment for good reason, these terms as defined in the agreements, he is entitled to the following: (i) a lump sum payment in an amount equal to twelve (12) months of his then current base salary and (ii) a lump sum payment in an amount equal to one hundred percent (100%) of the target annual bonus for the period in which his employment is terminated and (iii) continuation of benefit coverage for up to twelve (12) months.

If any of Drs. Or or Rottinghaus or Messrs. Gardiner or Mellett is terminated involuntarily without cause other than within twelve (12) months of a change in control transaction or voluntarily terminates his employment for good reason, these terms as defined in the agreements, then each is entitled to the following: (i) a lump sum payment in an amount equal to six (6) months of his or her then current base salary and (ii) continuation of benefit coverage for up to six (6) months.

In addition, if any of Drs. Luly, Or or Rottinghaus or Messrs. Gardiner or Mellett is involuntary terminated without cause or is constructively terminated, and such termination occurs within twelve months of a change of control transaction, these terms as defined in the agreements, all unvested stock options and restricted stock units granted to that executive shall immediately become fully vested and exercisable or become vested and settle, as the case may be, and all unvested performance share units shall vest and issue with respect to the target number of shares.

The following tables shows the potential payments due to each of our NEOs (i) upon termination of employment prior to a change in control and (ii) upon termination of employment within 12 months following a change of control; assuming such termination were to have occurred as of September 30, 2022.

	Termination Without Cause (1)					Total (\$)
	Not in Connection with a Change of Control					
	Salary (\$)	Bonus (\$)⁽²⁾	Benefits (\$)⁽³⁾	Other (\$)⁽⁴⁾	Value of Modified Equity Awards (\$)⁽⁵⁾	
Jay R. Luly, Ph.D.	733,400	513,380	21,259	12,672	—	1,280,711
Scott T. Rottinghaus, M.D.	262,500	—	15,202	5,969	—	283,671
Yat Sun Or, Ph.D.	252,500	—	10,459	48,057	—	311,016
Nathaniel S. Gardiner, J.D.	230,700	—	10,629	13,975	—	255,304
Paul J. Mellett	228,650	—	10,552	18,894	—	258,096

- (1) “Cause” is defined as a vote of our Board of Directors to dismiss the NEO as a result of (i) any act of the NEO constituting criminal financial dishonesty against Enanta; (ii) the NEO’s engagement in any other act of dishonesty, fraud, intentional misrepresentation, moral turpitude, illegality or harassment determined in good faith by our Board of Directors to be reasonably likely to adversely affect Enanta’s business or reputation or negligently expose Enanta to civil or criminal liability; or (iii) the NEO’s repeated failure to follow the directives of the Board.
- (2) Represents lump sum payment made as of date of termination based on 100% of the CEO’s target bonus.
- (3) Consists of health and dental benefits and life insurance coverage. The value is based upon the type of insurance coverage we carried for each executive officer as of September 30, 2022 and is valued at the premiums in effect on September 30, 2022.
- (4) Represents accrued vacation pay due to the executive officer as of September 30, 2022.
- (5) No options, restricted stock units or performance share units would vest as a result of the termination of the executive officer’s employment without cause not in connection with a change of control.

**Termination Without Cause(1)
Following a Change of Control**

	<u>Salary (\$)</u>	<u>Bonus (\$)⁽²⁾</u>	<u>Benefits (\$)⁽³⁾</u>	<u>Other (\$)⁽⁴⁾</u>	<u>Value of Modified Equity Awards (\$)⁽⁵⁾</u>	<u>Total (\$)</u>
Jay R. Luly, Ph.D.	1,100,100	770,070	31,888	12,672	5,948,348	7,863,078
Scott T. Rottinghaus, M.D.	525,000	210,000	30,404	5,969	1,371,443	2,142,816
Yat Sun Or, Ph.D.	505,000	202,000	20,918	48,057	2,332,712	3,108,687
Nathaniel S. Gardiner, J.D.	461,400	184,560	21,259	13,975	2,182,289	2,863,483
Paul J. Mellett	457,300	182,920	21,103	18,894	2,182,289	2,862,506

- (1) “Change in control” is defined as (a) the acquisition of 50% or more of our common stock (including shares convertible into common stock) by any person, entity or “group” (as such term is defined in Section 13(d) or 14(d)(2) of the Securities Exchange Act of 1934, as amended); (b) a change in the majority of the directors on the board of directors being directors who were not nominated by the incumbent board; (c) a merger or similar combination after which 50% or more of our voting stock or any other surviving corporation that is a successor to us is not held by the persons having beneficial ownership of us immediately prior to such merger or combination, or (d) the sale of all or substantially all of our assets.
- (2) Amount represents 100% of the executive’s target bonus for the fiscal year in which termination of employment occurs. In the case of our CEO, the amount represents 150% of his target bonus.
- (3) Consists of health, dental and vision benefits and life insurance coverage. The value is based upon the type of insurance coverage we carried for each executive officer as of September 30, 2022 and is valued at the premiums in effect on September 30, 2022.
- (4) Represents accrued vacation pay due to the executive officer as of September 30, 2022.
- (5) Represents the intrinsic value, as of September 30, 2022, of all unvested stock options, restricted stock units and performance share units that would vest as a result of the termination of the executive officer’s employment as of September 30, 2022, in connection with a change of control.

CEO Pay Ratio

In accordance with Section 953(b) of the Dodd-Frank Act and Item 402(u) of Regulation S-K, we are required to disclose the ratio of the annual total compensation of our principal executive officer to the median of the annual total compensation of all of our employees other than our principal executive officer. For fiscal 2022 the annual total compensation for Jay R. Luly, Ph.D., our Chief Executive Officer, as reported in our Summary Compensation Table, was \$7,272,656, and the annual total compensation for our median employee was \$249,345, resulting in an estimated pay ratio of approximately 29:1.

We identified the median employee as of September 30, 2022, by aggregating for each employee employed on that date (i) base salary or wages actually paid in fiscal 2022, (ii) cash incentive compensation actually paid in fiscal 2022, (iii) the grant date fair value of equity awards granted in fiscal 2022 determined in accordance with FASB ASC Topic 718, and (iv) the company-paid 401(k) Plan contribution made during fiscal year 2022. We chose this methodology because we believed it was reasonably representative of our employee compensation. We then ranked our employees from lowest to highest using this compensation measure. This calculation was performed for all of our employees who were employed on September 30, 2022, excluding Dr. Luly, which totaled 159 employees, all of whom are based in the United States. Since that resulted in an odd number of employees, we selected the employee ranked 80th on the list as our “median employee” for purposes of calculating the pay ratio and then determined that employee’s annual total compensation in the same manner as we determined Dr. Luly’s compensation for purposes of the Summary Compensation Table.

DIRECTOR COMPENSATION

The following table summarizes compensation paid to our non-employee directors during or with respect to the fiscal year ended September 30, 2022.

<u>Non-Employee Directors:</u>	<u>Fees Earned or Paid in Cash (\$)</u>	<u>Option Awards (\$)⁽¹⁾⁽²⁾</u>	<u>All Other Compensation (\$)</u>	<u>Total (\$)</u>
Bruce L.A. Carter, Ph.D.	95,000	223,605	—	318,605
Mark G. Foletta	73,750	223,605	—	297,355
Yujiro Hata	61,250	223,605	—	284,855
Kristine Peterson	68,750	223,605	—	292,355
Lesley Russell, MBChB, MRCP	63,750	223,605	—	287,355
Terry C. Vance	76,250	223,605	—	299,855
<u>Employee Directors:</u>				
Jay R. Luly, Ph.D. ⁽³⁾	—	—	—	—

- (1) Amounts shown represent the aggregate grant date fair value of the option awards granted on March 2, 2022, to our non-employee directors at the time of the 2022 annual meeting. These grant date fair values were computed in accordance with FASB Topic ASC 718. These amounts do not correspond to the actual value that will be recognized by the non-employee director with respect to such awards. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our financial statements included in our 2022 Form 10-K.
- (2) In 2022, each of our non-employee directors at the time of the 2022 annual meeting was awarded an option to purchase 7,500 shares, which vests monthly until our next annual meeting of stockholders.

The following sets forth the aggregate number of shares underlying outstanding options as of September 30, 2022 held by each director included in the table:

<u>Director</u>	<u>Option Shares Outstanding</u>
Bruce L.A. Carter, Ph.D.	51,000
Mark G. Foletta	32,000
Yujiro Hata	20,644
Kristine Peterson	46,250
Lesley Russell, MBChB, MRCP	50,000
Terry C. Vance	67,440
Jay R. Luly, Ph.D.*	—

- * Excludes outstanding options to purchase an aggregate 961,672 shares awarded to Dr. Luly in his capacity as President and Chief Executive Officer of Enanta, outstanding restricted stock units for 45,575 shares with service-based vesting and outstanding PSUs and rTSRUs for an aggregate of 59,400 shares, which is the target number of shares that may be earned by Dr. Luly under various unit awards.
- (3) Dr. Luly receives no compensation for his service on the Board. All of his compensation is described above in this proxy statement under the heading “Executive Compensation – Summary Compensation Table.”

Director Compensation Policy

Our non-employee directors received an annual retainer of \$50,000 starting in calendar 2022. The Chairman of our Board of Directors also received an additional retainer of \$35,000. In addition, all non-employee directors who served on one or more committees received the following committee fees:

<u>Committee</u>	<u>Chair</u>	<u>Other Member</u>
Audit Committee	\$20,000	\$10,000
Compensation Committee	\$15,000	\$ 7,500
Nominating and Corporate Governance Committee . . .	\$10,000	\$ 5,000

Other than the annual retainers and committee fees described above, non-employee directors were not entitled to receive any cash fees in connection with their service on our Board in 2022. Equity awards to our non-employee directors are made on the date of our annual meeting of stockholders and, in the case of new directors, when they join our board of directors. At our 2022 annual meeting of stockholders, each non-employee director who had served at least six months prior to the annual meeting was awarded an option to purchase 7,500 shares, vesting monthly over the year of service until the next annual meeting. Any new director is granted an option award upon joining our board of directors, which would typically be approximately 1.7 times the most recent annual grant to non-employee directors and would vest monthly over three years.

Our Board has approved limitations on non-employee director compensation, which are set forth in our 2019 Equity Plan. These limitations, which apply to total annual compensation, including annual retainer, committee fees and equity awards, are \$900,000 in the year of initial election (when an initial equity award is granted) and \$600,000 for each year thereafter.

AUDIT COMMITTEE REPORT

The following is the report of the Audit Committee with respect to Enanta's audited financial statements for the year ended September 30, 2022.

The purpose of the Audit Committee is to assist the Board in fulfilling its responsibility to oversee Enanta's accounting and financial reporting, internal controls and audit functions. The Audit Committee Charter describes in greater detail the full responsibilities of the Committee and is available in the "Investors – Corporate Governance" section of our website at www.enanta.com. The Audit Committee is comprised entirely of independent directors as defined by applicable Nasdaq Stock Market standards.

Management is responsible for our internal controls and the financial reporting process. PricewaterhouseCoopers LLP, our independent registered public accounting firm, is responsible for performing an independent audit of our consolidated financial statements and internal control over financial reporting in accordance with the standards established by the Public Company Accounting Oversight Board (United States) and issuing a report thereon. The Committee's responsibility is to monitor these processes. The Audit Committee has reviewed and discussed the consolidated financial statements with management and PricewaterhouseCoopers LLP.

In the course of its oversight of Enanta's financial reporting process, the Audit Committee:

- reviewed and discussed with management and PricewaterhouseCoopers LLP Enanta's audited financial statements for the fiscal year ended September 30, 2022;
- discussed with PricewaterhouseCoopers LLP the matters required to be discussed by Public Company Accounting Oversight Board Auditing Standard No. 16, *Communications with Audit Committees*;
- received written disclosures and the letter from PricewaterhouseCoopers LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant's communications with the Audit Committee concerning independence;
- reviewed with management and PricewaterhouseCoopers LLP Enanta's critical accounting policies;
- discussed with management the quality and adequacy of Enanta's internal controls;
- discussed with PricewaterhouseCoopers LLP any relationships that may impact their objectivity and independence; and
- considered whether the provision of non-audit services by PricewaterhouseCoopers LLP is compatible with maintaining its independence.

Based on the foregoing review and discussions, the Committee recommended to the Board of Directors that the audited financial statements be included in Enanta's Annual Report on Form 10-K for the year ended September 30, 2022 for filing with the Securities and Exchange Commission.

By the Audit Committee,
Mark G. Foletta, Chair
Lesley Russell, MBChB, MRCP
Terry C. Vance

January 20, 2023

Audit Fees

PricewaterhouseCoopers LLP, an independent registered public accounting firm, audited our financial statements for the year ended September 30, 2022. The Audit Committee, under delegated authority of the Board of Directors, has appointed PricewaterhouseCoopers LLP to serve as our independent registered public accounting firm for the fiscal year ending September 30, 2022. Representatives of PricewaterhouseCoopers LLP are expected to attend the annual meeting to respond to appropriate questions, and they will have the opportunity to make a statement if they desire.

The aggregate fees for audit and other services provided by PricewaterhouseCoopers LLP for fiscal years 2022 and 2021 are as follows:

	<u>2022</u>	<u>2021</u>
Audit Fees ⁽¹⁾	\$1,172,913	\$736,941
Tax Fees ⁽²⁾	63,944	63,944
All Other Fees ⁽³⁾	3,081	2,900
Total	<u>\$1,239,938</u>	<u>\$803,785</u>

- (1) Audit fees represent fees for professional services provided in connection with the audit of our financial statements, audit of our internal control over financial reporting, review of our quarterly financial statements, audit of new system implementations during 2022, audit services provided in connection with other statutory or regulatory filings and issuance of a comfort letter associated with the filing of an open market sale agreement in August 2022.
- (2) Tax fees were for services related to (a) tax compliance including sales and use taxes and (b) tax planning. The 2022 tax fees consisted of \$63,944 for tax compliance. The 2021 tax fees consisted of \$58,944 for tax compliance and \$5,000 for assistance with filing residency certificates.
- (3) All other fees for 2022 and 2021 relate to technical research material fees.

Our Audit Committee has adopted procedures requiring the pre-approval of all non-audit (including tax) services performed by our independent registered public accounting firm in order to assure that these services do not impair the auditor's independence. These procedures generally approve the performance of specific services subject to a cost limit for all such services. This general approval is to be reviewed, and if necessary modified, at least annually. Management must obtain the specific prior approval of the Audit Committee for each engagement of the independent registered public accounting firm to perform other audit-related or other non-audit services. For engagements for audit-related or tax-related services within a specified dollar limit, the Chair of the Audit Committee has authority to provide such prior approval, and he reports to the full committee whenever he has exercised that authority. The Audit Committee does not delegate its responsibility to approve services performed by the independent registered public accounting firm to any member of management.

The standard applied by the Audit Committee in determining whether to grant approval of any type of non-audit service, or of any specific engagement to perform a non-audit service, is whether the services to be performed, the compensation to be paid therefore and other related factors are consistent with the independent registered public accounting firm's independence under guidelines of the SEC and applicable professional standards. Relevant considerations include whether the work product is likely to be subject to, or implicated in, audit procedures during the audit of our financial statements, whether the independent registered public accounting firm would be functioning in the role of management or in an advocacy role, whether the independent registered public accounting firm's performance of the service would enhance our ability to manage or control risk or improve audit quality, whether such performance would increase efficiency because of the independent registered public accounting firm's familiarity with our business, personnel, culture, systems, risk profile and other factors, and whether the amount of fees involved, or the non-audit services portion of the total fees payable to the independent registered public accounting firm in the period, would tend to reduce the independent registered public accounting firm's ability to exercise independent judgment in performing the audit.

STOCKHOLDER MATTERS

Stockholder Recommendations for Director Nominations

Any stockholder wishing to recommend a director candidate for consideration by the Nominating and Corporate Governance Committee should provide the following information to the Chair of the Nominating and Corporate Governance Committee, Enanta Pharmaceuticals, Inc., 500 Arsenal Street, Watertown, Massachusetts 02472:

- (a) a brief statement outlining the reasons the nominee would be an effective director for Enanta;
- (b) (i) the name, age, and business and residence addresses of the candidate, (ii) the principal occupation or employment of the candidate for the past five years, as well as information about any other Board of Directors and board committees on which the candidate has served during that period, (iii) the number of shares of Enanta stock, if any, beneficially owned by the candidate and (iv) details of any business or other significant relationship the candidate has ever had with Enanta;
- (c) (i) the stockholder's name and record address and the name and address of the beneficial owner of Enanta shares, if any, on whose behalf the proposal is made and (ii) the number of shares of Enanta stock that the stockholder and any such other beneficial owner beneficially own; and
- (d) the other information specified in Enanta's Bylaws as then in effect. The Committee may seek further information from or about the stockholder making the recommendation, the candidate, or any such other beneficial owner, including information about all business and other relationships between the candidate and the stockholder and between the candidate and any such other beneficial owner.

Other Stockholder Proposals

Any stockholder proposing to bring any business other than a director candidate before an annual meeting of stockholders, which business must relate to a proper matter under Delaware law for stockholder action, must provide the following information to the Chair of the Nominating and Corporate Governance Committee:

- (a) a brief description of the business desired to be brought before the annual meeting;
- (b) the text of the proposal (including the exact text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend the bylaws, the exact text of the proposed amendment);
- (c) the reasons for conducting such business at the annual meeting;
- (d) the proposing stockholder's name and record address and the name and address of the beneficial owner of Enanta shares, if any, on whose behalf the proposal is made; and
- (e) the other information specified in Enanta's Bylaws as then in effect.

Deadline for Stockholder Proposals and Director Nominations

In order for a stockholder proposal to be considered for inclusion in Enanta's proxy materials for the annual meeting of our stockholders to be held in 2024 (the "2024 Annual Meeting"), it must be received by Enanta at 500 Arsenal Street, Watertown, Massachusetts 02472 (or such other address as is listed as Enanta's primary executive offices in its periodic reports under the Securities Exchange Act of 1934) no later than September 22, 2023.

In addition, Enanta's Bylaws require a stockholder who wishes to bring business before the meeting, but does not intend for such business to be included in our proxy statement, or who wishes to propose director nominations at the 2024 Annual Meeting, to give advance written notice to Enanta's Secretary not less than 90 days nor more than 120 days before the first anniversary of the 2023 Annual Meeting; *provided, however*, if our

next annual meeting is advanced more than 20 days or delayed more than 60 days after the anniversary of the 2023 Annual Meeting, such notice must be received in writing no earlier than the 120th day prior to such annual meeting and by the later of the close of business on the 90th day prior to such annual meeting and the 10th day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever occurs first. Accordingly, assuming the 2024 Annual Meeting is held on March 2, 2024, such advance written notice would need to be given between November 3, 2023 and December 3, 2023.

Universal Proxy Rules

To comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than Enanta's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than January 2, 2024. If the date of the 2024 Annual Meeting is more than 30 days before or after March 2, 2024, stockholders who intend to solicit proxies in support of director nominees other than Enanta's nominees must provide such notice by the later of 60 days prior to the meeting or the 10th day after Enanta first publicly announces the date of the meeting.

Appendix A

Reflects Increase in Authorized Shares Proposed
for Approval at the March 2, 2023 Annual Meeting

ENANTA PHARMACEUTICALS, INC.

2019 Equity Incentive Plan

1. Purpose

The purpose of this 2019 Equity Incentive Plan (this “*Plan*”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “*Company*”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “*Company*” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “*Code*”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the “*Board*”).

2. Eligibility

All of the Company’s employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and advisors are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as amended (the “*Securities Act*”), or any successor form), are eligible to be granted Awards under this Plan. Each person who is granted an Award under this Plan is deemed a “*Participant*.” “*Award*” means Options (as defined in Section 5), SARs (as defined in Section 6), Restricted Stock (as defined in Section 7), Restricted Stock Units (as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8).

3. Administration and Delegation

(a) Administration by Board of Directors. This Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to this Plan as it shall deem advisable. The Board may construe and interpret the terms of this Plan and any Award certificate issued or Award agreement entered into under this Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in this Plan or any Award in the manner and to the extent it shall deem expedient, and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in this Plan or in any Award.

(b) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under this Plan to one or more committees or subcommittees of the Board (a “*Committee*”). All references in this Plan to the “*Board*” shall mean the Board or a Committee of the Board or the officers referred to in Section 3(c) to the extent that the Board’s powers or authority under this Plan have been delegated to such Committee or officers.

(c) Delegation to Officers. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to grant Options and other Awards that constitute rights under Delaware law (subject to any limitations under this Plan) to employees or officers of the Company and to

exercise such other powers under this Plan as the Board may determine, *provided* that the Board shall fix the terms of such Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to such Awards that the officers may grant; *provided further*, however, that no officer shall be authorized to grant such Awards to any “executive officer” of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”)) or to any “officer” of the Company (as defined by Rule 16a-1 under the Exchange Act).

4. Stock Available for Awards

(a) Number of Shares; Share Counting.

(1) Authorized Number of Shares. Subject to adjustment under Section 9, Awards may be made under this Plan (any or all of which Awards may be in the form of Incentive Stock Options, as defined in Section 5(b)) for up to such number of shares of common stock, par value \$.01 per share, of the Company (the “*Common Stock*”) as is equal to the sum of:

(A) 4,575,000 shares of Common Stock; plus

(B) all shares of Common Stock reserved for issuance under the Company’s 2012 Equity Incentive Plan, as amended through October 1, 2018 (the “*2012 Plan*”) and not issued as of the date and time of stockholder approval of this Plan (including any shares reserved for issuance under the Company’s 1995 Equity Incentive Plan, as amended, that become available under the 2012 Plan), and including the 582,637 additional shares of Common Stock added on October 1, 2018 by the provision for automatic annual increases under the 2012 Plan, but not including any further increases under such provision, which provision shall have no further effect upon stockholder approval of this Plan; plus

(C) all shares of Common Stock reserved for issuance upon exercise of options or unit awards that are outstanding as of the date and time of stockholder approval of this Plan and that subsequently expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part or result in any Common Stock not being issued and such shares becoming available for the grant of Awards under this Plan pursuant to Section 4(a)(2)(B).

For the avoidance of doubt, shares of Common Stock reserved for issuance under the 2012 Plan can only become available for issuance under this Section 4(a)(1)(C), if they are not issuable or issued under awards made under the 2012 Plan.

(D) Shares issued under this Plan may consist in whole or in part of authorized but unissued shares or treasury shares.

(2) Share Counting. For purposes of counting the number of shares available for the grant of Awards under this Plan:

(A) all shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under this Plan; *provided, however*, that (i) SARs that may be settled only in cash shall not be so counted and (ii) if the Company grants an SAR in tandem with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a “*Tandem SAR*”), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other’s exercise will not restore shares to this Plan;

(B) if any Award under this Plan or, as applicable, the 2012 Plan (i) expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii) results in any Common Stock not being issued (including as a result of an SAR that could be settled either in

cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall become available for the grant of Awards under this Plan (even if previously granted under the 2012 Plan); *provided, however*, that (1) in the case of Incentive Stock Options, the foregoing shall be subject to any limitations under the Code, (2) in the case of the exercise of an SAR, the number of shares counted against the shares available under this Plan shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3) the shares covered by a tandem SAR shall not again become available for grant upon the expiration or termination of such tandem SAR;

(C) shares of Common Stock delivered (either by actual delivery, attestation, or net exercise) to the Company by a Participant under this Plan or the 2012 Plan to (i) purchase shares of Common Stock upon the exercise of an Award or (ii) satisfy tax withholding obligations (including shares retained from the Award creating the tax obligation) shall not be added back to the number of shares available for the future grant of Awards under this Plan.

(D) shares of Common Stock repurchased by the Company in the open market with the proceeds of the exercise price of an option may not be reissued under this Plan.

(b) Substitute Awards. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in this Plan. Substitute Awards shall not count against the overall share limit set forth in Section 4(a)(1) or any sublimit contained in this Plan, except as may be required by reason of Section 422 and related provisions of the Code.

(c) Non-Employee Director Aggregate Compensation Limit. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a non-employee director of the Company with respect to any period commencing on the date of the Company's annual meeting of stockholders for a particular year and ending on the day immediately prior to the date of the Company's annual meeting of stockholders for the next subsequent year, including Awards granted and cash fees paid or payable by the Company to such non-employee director, will not exceed (i) \$600,000 in total value or (ii) in the event such non-employee director is first appointed or elected to the Board during such period, \$900,000 in total value. The value of any Awards included in the calculation of such total value shall be based on the grant date fair value of such Awards for financial reporting purposes, and any compensation shall be counted towards these limits for the service year in which it is earned (and not when settled or paid in the event any such compensation is deferred).

5. Stock Options

(a) General. The Board may grant options to purchase Common Stock (each, an "*Option*") and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.

(b) Incentive Stock Options. An Option that the Board intends to be an "incentive stock option" as defined in Section 422 of the Code (an "*Incentive Stock Option*") shall only be granted to employees of Enanta Pharmaceuticals, Inc., any of Enanta Pharmaceuticals, Inc.'s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated a "*Nonstatutory Stock Option*." The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. No Incentive

Stock Option may be granted hereunder more than 10 years after the Effective Date (as defined in Section 11(d) and subject to reset as provided therein).

(c) Exercise Price. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option certificate. The exercise price shall be not less than 100% of the Fair Market Value per share of Common Stock on the date the Option is granted; *provided* that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. “*Fair Market Value*” of Common Stock on any given date means the fair market value of Common Stock determined in good faith by the Board; *provided*, however, that if Common Stock is admitted to quotation on a national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last preceding such date for which there are market quotations.

(d) Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement; *provided, however*, that no Option will be granted with a term in excess of ten (10) years.

(e) Exercise of Options. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section 5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise.

(f) Payment Upon Exercise. Common Stock purchased upon the exercise of an Option granted under this Plan shall be paid for as follows:

(1) in cash or by check, payable to the order of the Company;

(2) except as may otherwise be provided in the applicable Option certificate or approved by the Board, in its sole discretion, by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;

(3) to the extent provided for in the applicable Option certificate or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, *provided* (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;

(4) to the extent provided for in the applicable Nonstatutory Stock Option certificate or approved by the Board in its sole discretion, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares underlying the portion of the Option being exercised, less (ii) such number of shares as is equal to (A) the aggregate exercise price for the portion of the Option being exercised divided by (B) the Fair Market Value on the date of exercise;

(5) to the extent permitted by applicable law and *provided* for in the applicable Option certificate or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or

(6) by any combination of the above permitted forms of payment.

(g) Limitation on Repricing. Unless such action is approved by the Company's stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding Option granted under this Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option, (2) cancel any outstanding option (whether or not granted under this Plan) and grant in substitution therefor new Awards under this Plan (other than Awards granted pursuant to Section 4(b)) covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3) cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the then-current Fair Market Value, other than pursuant to Section 9, or (4) take any other action under this Plan that constitutes a "repricing" within the meaning of the rules of the NASDAQ Stock Market.

6. Stock Appreciation Rights

(a) General. The Board may grant Awards consisting of stock appreciation rights ("SARs") entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to Section 6(b). The date as of which such appreciation is determined shall be the exercise date.

(b) Measurement Price. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR certificate. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; *provided* that if the Board approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date.

(c) Duration of SARs. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; *provided, however*, that no SAR will be granted with a term in excess of 10 years.

(d) Exercise of SARs. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board.

(e) Limitation on Repricing. Unless such action is approved by the Company's stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding SAR granted under this Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such outstanding SAR, (2) cancel any outstanding SAR (whether or not granted under this Plan) and grant in substitution therefor new Awards under this Plan (other than Awards granted pursuant to Section 4(b)) covering the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current measurement price per share of the cancelled SAR, (3) cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current Fair Market Value, other than pursuant to Section 9, or (4) take any other action under this Plan that constitutes a "repricing" within the meaning of the rules of the NASDAQ Stock Market.

7. Restricted Stock; Restricted Stock Units

(a) General. The Board may grant Awards entitling recipients to acquire shares of Common Stock ("*Restricted Stock*"), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests ("*Restricted Stock Units*") (Restricted Stock and Restricted Stock Units are each referred to herein as a "*Restricted Stock Award*").

(b) Terms and Conditions for All Restricted Stock Awards. The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.

(c) Additional Provisions Relating to Restricted Stock.

(1) Dividends. Any dividends (whether paid in cash, stock or property) declared and paid by the Company with respect to shares of Restricted Stock (“*Accrued Dividends*”) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock.

(2) Other Restrictions. The Company may require that stock transfer restrictions be implemented by the Company’s transfer agent with respect to shares of Restricted Stock, and that dividends or distributions paid on such Restricted Stock shall be deposited in escrow with the Company (or its designee) by the Participant, together with a stock power endorsed in blank. At the expiration of the applicable restriction periods, the Company (or such designee) shall instruct the Company’s transfer agent to remove the restrictions on transfer regarding the applicable shares no longer subject to such restrictions and deliver them to the Participant, or if the Participant has died, to his or her Designated Beneficiary in accordance with appropriate instructions for electronic delivery of uncertificated shares. “*Designated Beneficiary*” means (i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the absence of an effective designation by a Participant, the Participant’s estate.

(d) Additional Provisions Relating to Restricted Stock Units.

(1) Settlement. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or (if so provided in the applicable Award certificate) an amount of cash equal to the Fair Market Value of one share of Common Stock. The Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section 409A of the Code.

(2) Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units.

(3) Dividend Equivalents. The Award certificate for Restricted Stock Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“*Dividend Equivalents*”). To the extent provided in the Award certificate, Dividend Equivalents may be credited to an account for the Participant and may be settled in cash and/or shares; provided, however, that they shall be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which they are credited. In no case shall Dividend Equivalents on Restricted Stock Units be paid before such units vest.

8. Other Stock-Based Awards

(a) General. Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property (“*Other Stock-Based Awards*”), may be granted hereunder to Participants. In no case shall Dividend Equivalents with respect to Other Stock-Based Awards be paid before such Awards vest. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under this Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine.

(b) Terms and Conditions. Subject to the provisions of this Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto.

9. Adjustments for Changes in Common Stock and Certain Other Events

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number and class of securities available under this Plan, (ii) the share counting rules set forth in Section 4(a), (iii) the number and class of securities and exercise price per share of each outstanding Option, (iv) the share and per-share provisions and the measurement price of each outstanding SAR, (v) the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi) the share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.

(b) Reorganization Events.

(1) Definition. A “*Reorganization Event*” shall mean: (a) any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company.

(2) Consequences of a Reorganization Event on Awards Other than Restricted Stock.

(A) In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award certificate or agreement or another agreement between the Company and the Participant): (i) provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all of the Participant’s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “*Acquisition Price*”), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A) the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over (II) the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. In taking any of the actions permitted under this

Section 9(b)(2), the Board shall not be obligated by this Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.

(B) Notwithstanding the terms of Section 9(b)(2)(A), in the case of outstanding Restricted Stock Units that are subject to Section 409A of the Code: (i) if the applicable Restricted Stock Unit certificate provides that the Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”, then no assumption or substitution shall be permitted pursuant to clause (i) of Section 9(b)(2)(A) and the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit certificate; and (ii) the Board may only undertake the actions set forth in clauses (iii), (iv) or (v) of Section 9(b)(2)(A) if the Reorganization Event constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such action is permitted or required by Section 409A of the Code; if the Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by Section 409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i) of Section 9(b)(2)(A), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.

(C) For purposes of clause (i) of Section 9(b)(2)(A), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); *provided, however*, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event.

(3) Consequences of a Reorganization Event on Restricted Stock. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock; *provided, however*, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied.

10. General Provisions Applicable to Awards

(a) Transferability of Awards. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option or Awards subject to

Section 409A of the Code, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; *provided, however*, except with respect to Awards subject to Section 409A of the Code, that the Board may permit or provide in an Award solely for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; *provided further*, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section 10(a) shall be deemed to restrict a transfer to the Company.

(b) Documentation. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in this Plan.

(c) Board Discretion. Except as otherwise provided by this Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.

(d) Termination of Status. The Board shall determine the effect of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant on any Award of the Participant and the extent to which, and the period during which, the Participant, or the Participant's legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award.

(e) Withholding. The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.

(f) Amendment of Award. Except as set forth in Section 5(g) and 6(e), the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant's consent to such action shall be required unless (i) the Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant's rights under this Plan or (ii) the change is permitted under Section 9. In addition, the Board may not take any other action that is considered a direct or indirect "repricing" for purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Common Stock is listed, including any other action that is treated as a repricing under generally accepted accounting principles in the United States of America.

(g) Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to this Plan or to remove restrictions from shares previously issued or delivered under this Plan

until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company's counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations.

(h) Acceleration. The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.

(i) Performance Awards.

(1) Awards. Restricted Stock Awards and Other Stock-Based Awards under this Plan may be made subject to the achievement of performance measures pursuant to this Section 10(i) ("*Performance Awards*"). Subject to Section 10(i)(4), no Performance Awards shall vest prior to the first anniversary of the date of grant.

(2) Performance Measures. For any Award that is designed to be a Performance Award, the Committee may specify the degree of granting, vesting and/or payout that shall be subject to the achievement of one or more objective performance measures at, below, or above target measures, as the Committee may determine. Such goals may reflect absolute entity or business unit performance or a relative comparison to the performance of a peer group of entities or other external measure of the selected performance criteria and may be absolute in their terms or measured against or in relationship to other companies comparably, similarly or otherwise situated. Such performance measures: (i) may vary by Participant and may be different for different Awards; and (ii) may be particular to a Participant or the department, branch, line of business, subsidiary or other unit in which the Participant works and may cover such period as may be specified by the Committee.

(3) Other. The Committee shall have the power to impose such other restrictions on Performance Awards as it may deem necessary or appropriate.

11. Miscellaneous

(a) No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award by virtue of the adoption of this Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under this Plan, except as expressly provided in the applicable Award.

(b) No Rights As Stockholder. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares.

(c) Clawback. Notwithstanding anything to the contrary in this Plan, the Company may recover from a Participant any compensation received from any Award (whether or not settled) or cause a Participant to forfeit any Award (whether or not vested) to the extent that the Committee or the Board determines that such forfeiture should occur in accordance with any so-called "clawback" or recoupment policy duly adopted by the Board and then in effect.

(d) Effective Date and Term of Plan. This Plan shall become effective on the date this Plan is approved by the Company's stockholders (the "*Effective Date*"). No Awards shall be granted under this Plan after the expiration of ten (10) years from the Effective Date, but Awards previously granted may extend beyond that date.

Any increase in the maximum number of shares that may be issued under this Plan (other than an increase merely reflecting a change in the number of outstanding shares of the Company's capital stock, such as a stock dividend or stock split) shall be considered the adoption of a new plan requiring stockholder approval under Section 422 of the Code, and any such stockholder approval shall automatically reset the Effective Date to the date of such approval and the term of this Plan shall then be extended thereby until ten (10) years from such date.

(e) Amendment of Plan. The Board may amend, suspend or terminate this Plan or any portion thereof at any time provided that no amendment that would require stockholder approval under the rules of the NASDAQ Stock Market may be made effective unless and until the Company's stockholders approve such amendment. In addition, if at any time the approval of the Company's stockholders is required as to any other modification or amendment under Section 422 of the Code or any successor provision with respect to Incentive Stock Options, the Board may not implement such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to this Plan adopted in accordance with this Section 11(e) shall apply to, and be binding on the holders of, all Awards outstanding under this Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under this Plan. No Award shall be made that is conditioned upon stockholder approval of any amendment to this Plan unless the Award provides that (i) it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no more than 12 months from the date of grant and (ii) it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval.

(f) Authorization of Sub-Plans (including for Awards to non-U.S. Employees). The Board may from time to time establish one or more sub-plans under this Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to this Plan containing (i) such limitations on the Board's discretion under this Plan as the Board deems necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with this Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of this Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.

(g) Compliance with Section 409A of the Code. Except as provided in individual Award certificates or agreements initially or by amendment, if and to the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to this Plan in connection with his or her employment termination constitutes "nonqualified deferred compensation" within the meaning of Section 409A of the Code and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of "separation from service" (as determined under Section 409A of the Code) (the "*New Payment Date*"), except as Section 409A of the Code may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.

The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under this Plan are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not to satisfy the conditions of that section.

(h) Limitations on Liability. Notwithstanding any other provisions of this Plan, no individual acting as a director, officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with this Plan,

nor will such individual be personally liable with respect to this Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company. The Company will indemnify and hold harmless each director, officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of this Plan has been or will be delegated, against any cost or expense (including attorneys' fees) or liability (including any sum paid in settlement of a claim with the Board's approval) arising out of any act or omission to act concerning this Plan unless arising out of such person's own fraud or bad faith.

(i) Governing Law. The provisions of this Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware.

*Approved by Board on Nov. 17, 2018, and by stockholders on Feb. 28, 2019;
Amended by the Board on January 8, 2021 and by stockholders on March 2, 2021;
Amended by the Board on January 7, 2022 and by stockholders on March 3, 2022.
Amended by the Board on January 2023, subject to stockholders approval.*